A Phase 2/3 interventional study of Etrasimod and Etrasimod in Crohn's Disease, sponsored by Pfizer. Terminated at 510 sites in 41 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by Pfizer · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Crohn Disease by Pfizer — none open to participants now, none under way, none of them phase 3. Crohn Disease · Pfizer.
Among the 17 studies in Crohn Disease by Pfizer, this one has the largest enrollment of the 11 interventional ones that give a count, is the only one that started in 2020, is the only one in phase 2/3, and was the 16th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →None of the 17 studies in Crohn Disease by Pfizer is open now. The open studies under Crohn Disease, anywhere →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 1
First in 2002; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 379 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 180 across the 11 interventional studies, 1,431 across the 5 observational. Of the 17 that completed or were terminated, 14 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Crohn Disease by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adult participants with moderately to severely active Crohn's disease (CD) who are refractory or intolerant to at least 1 of the current therapies for CD (ie, corticosteroids, immunosuppressants, or biologics). The overall duration of this study is up to 282 weeks, inclusive of the Screening Period, Treatment Period of up to 274 weeks (Induction, Extension or Maintenance, and Long-term Extension Periods), and the 4-Week Follow-Up Period for safety assessment.
This study includes 5 substudies:
Substudy A - Phase 2: A Phase 2, randomized, double-blind, substudy to assess the safety, tolerability, and efficacy of oral etrasimod therapy in participants with moderate to severe CD that supports the selection of an induction and maintenance dose(s) for Phase 3.
Substudy 1 - Phase 2: A Phase 2b randomized, double-blind, placebo-controlled, dose-ranging induction substudy to evaluate etrasimod as induction therapy and select an induction and maintenance dose(s) for continued evaluation in Phase 3.
Substudy 2 - Induction: A Phase 3 randomized, double-blind, placebo-controlled substudy to evaluate etrasimod as induction therapy.
Substudy 3 - Maintenance: A Phase 3 randomized, double-blind, placebo-controlled substudy to evaluate etrasimod as maintenance therapy. Participants from Substudy 1 and Substudy 2 will be enrolled in Substudy 3.
Substudy 4 - Long-Term Extension: A long-term extension substudy for participants who complete at least 52 weeks of treatment. Participants from Substudy 3 and Substudy A are planned to be enrolled in Substudy 4.
Eligibility criteria applicable to all substudies:
Inclusion Criteria:
Demonstrated inadequate response (ie, primary non-response), loss of response to, or intolerance to ≥ 1 of the following therapies for the treatment of CD:
Exclusion Criteria:
Inclusion Criteria for Substudy 3:
- Participants who entered the Extended Induction Period of Substudy 1 and Substudy 2 must have completed the Extended Induction -Week 6 Visit
Inclusion Criteria for Substudy 4:
- Participant must have completed the Week 52 Visit of Substudy 3 or the Week 66 Visit of Substudy A
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Etrasimod
Drug: Etrasimod
Drug: Placebo
Percentage of Participants With Endoscopic Response by Simple Endoscopic Score in Crohn's Disease (SES-CD) at Week 14: SSA
Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from study baseline in SES-CD. SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 bowel segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2= large ulcers and 3= very large ulcers. Ulcerated surface score: 0= none, 1= \<10%, 2= 10% - 30% and 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%, 2= 50% - 75%, and 3= \>75%. Presence of narrowing score: 0= none, 1= single, can be passed, 2= multiple, can be passed, 3= cannot be passed. Total SES-CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score indicated more severe disease.
Time frame: Week 14 of SSA
Percentage of Participants With Endoscopic Response by SES-CD at Week 14: SS1
Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from study baseline in SES-CD. SES-CD consisted of composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 bowel segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2= large ulcers and 3= very large ulcers. Ulcerated surface score: 0= none, 1= \<10%, 2= 10% - 30% and 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%, 2= 50% - 75%, and 3= \>75%. Presence of narrowing score: 0= none, 1= single, can be passed, 2= multiple can be passed, 3= cannot be passed. Total SES CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease. Multiple imputation (MI) method used; percentage calculated based on average response rate from MI datasets.
Time frame: Week 14 of SS1
Percentage of Participants With Clinical Remission by CDAI at Week 52: SS3 Responder Cohort
Clinical remission was considered as CDAI score \<150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); hematocrit (HCT): 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Time frame: Week 52 of study
Percentage of Participants With Clinical Remission by CDAI at Week 52: SS3 Non-Responder Cohort
Clinical remission was considered as CDAI score \<150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Time frame: Week 52 of study
Percentage of Participants With Endoscopic Response by SES-CD at Week 52: SS3 Responder Cohort
Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD consisted of composite score based on size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon; rectum. Size of ulcers score: 0=none, 1=aphthous ulcers,2=large ulcers,3=very large ulcers. Ulcerated surface score: 0= none, 1= \<10%, 2= 10% - 30%, 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%,2= 50%-75%,3= \>75%. Presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed,3=cannot be passed. Total SES CD=sum of each domain score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score= more severe disease.
Time frame: Week 52 of study
Percentage of Participants With Endoscopic Response by SES-CD at Week 52: SS3 Non-Responder Cohort
Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD consisted of composite score based on size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right, transverse; left colon; rectum. Size of ulcers score: 0=none, 1=aphthous ulcers,2=large ulcers,3=very large ulcers. Ulcerated surface score: 0= none, 1= \<10%, 2= 10% - 30%, 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%,2= 50%-75%,3= \>75%. Presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed,3=cannot be passed. Total SES CD=sum of each domain score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score= more severe disease.
Time frame: Week 52 of study
Percentage of Participants With Clinical Remission by CDAI at Week 14: SSA
Clinical remission was considered as CDAI score \<150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Time frame: Week 14 of SSA
Change From Baseline in SES-CD Score at Week 14: SSA
SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 bowel segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2= large ulcers and 3= very large ulcers. Ulcerated surface score: 0= none, 1= \<10%, 2= 10% - 30% and 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%, 2= 50% - 75%, and 3= \>75%. Presence of narrowing score: 0= none, 1= single, can be passed, 2= multiple, can be passed, 3= cannot be passed. Total SES-CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score indicated more severe disease.
Time frame: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Change From Baseline in CDAI Score at Week 14: SSA
CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Time frame: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Plasma Concentration of Etrasimod at 4 Hours Post-dose: SSA
The plasma concentration of etrasimod at 4 hours post-dose has been reported in this outcome measure.
Time frame: 4 hours post-dose on Day 1
Steady State Trough Concentration (Ctrough,ss) of Etrasimod From Week 2 to Week 14: SSA
The average steady-state Ctrough for Week 2 through 14 was calculated based on individual Ctrough data from Week 2, Week 6 and Week 14.
Time frame: From Week 2 to Week 14
Change From Baseline in Absolute Lymphocyte Count (ALC) at Week 14 in Induction Period: SSA
Time frame: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Percent Change From Baseline in ALC at Week 14 in Induction Period: SSA
Time frame: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Change From Baseline in ALC at Week 66 in Extension Period: SSA
Time frame: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Percent Change From Baseline in ALC at Week 66 in Extension Period: SSA
Time frame: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Change From Baseline in Fecal Calprotectin (FCP) Concentration at Week 14 in Induction Period: SSA
Time frame: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Percent Change From Baseline in FCP Concentration at Week 14 in Induction Period: SSA
Time frame: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Change From Baseline in FCP Concentration at Week 66 in Extension Period: SSA
Time frame: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Percent Change From Baseline in FCP Concentration at Week 66 in Extension Period: SSA
Time frame: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Change From Baseline in C-Reactive Protein (CRP) at Week 14 in Induction Period: SSA
Time frame: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Percent Change From Baseline in CRP at Week 14 in Induction Period: SSA
Time frame: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Change From Baseline in CRP at Week 66 in Extension Period: SSA
Time frame: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Percent Change From Baseline in CRP at Week 66 in Extension Period: SSA
Time frame: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Percentage of Participants With Clinical Remission by CDAI at Week 14: SS1
Clinical remission was considered as CDAI score \<150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease. MI method was used; percentage was calculated based on average response rate from MI datasets.
Time frame: Week 14 of SS1
Percentage of Participants With Clinical Remission by Patient Reported Outcomes 2 (PRO2) at Week 14: SS1
Clinical remission was defined as PRO2 score \<8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. MI method was used; percentage was calculated based on average response rate from MI datasets.
Time frame: Week 14 of SS1
Percentage of Participants With Clinical Remission by CDAI at Week 52 Among Participants With Clinical Remission by CDAI at SS3 Baseline: SS3 Responder Cohort
Clinical remission was CDAI score \<150. CDAI was a composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score: sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores= more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Time frame: Week 52 of study
Percentage of Participants With Clinical Remission by CDAI at Week 52 Among Participants With Clinical Remission by CDAI at SS3 Baseline: SS3 Non-Responder Cohort
Clinical remission was CDAI score \<150. CDAI was a composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score: sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores= more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Time frame: Week 52 of study
Percentage of Participants With Endoscopic Response at Week 52 Among Participants With Endoscopic Response at SS3 Baseline: SS3 Responder Cohort
Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD= composite score based on 4 components: size of ulcers, ulcerated surface, affected surface, presence of narrowing in 5 segments: ileum; right; transverse; left colon; rectum. Size of ulcers score: 0=none,1= aphthous ulcers, 2= large ulcers, 3= very large ulcers. Ulcerated surface score: 0= none,1= \<10%, 2= 10%-30%, 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%, 2= 50%-75%,3= \>75%. Presence of narrowing score: 0= none,1= single, can be passed, 2= multiple can be passed, 3= can't be passed. Total SES CD=sum of component scores for 5 bowel segments and ranged from 0 (no disease) - 60 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to FMD date.
Time frame: Week 52 of study
Percentage of Participants With Endoscopic Response at Week 52 Among Participants With Endoscopic Response at SS3 Baseline: SS3 Non-Responder Cohort
Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD= composite score based on 4 components: size of ulcers, ulcerated surface, affected surface, presence of narrowing in 5 segments: ileum; right; transverse; left colon; rectum. Size of ulcers score: 0=none,1= aphthous ulcers, 2= large ulcers, 3= very large ulcers. Ulcerated surface score: 0= none,1= \<10%, 2= 10%-30%, 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%, 2= 50%-75%,3= \>75%. Presence of narrowing score: 0= none,1= single, can be passed, 2= multiple can be passed, 3= can't be passed. Total SES CD=sum of component scores for 5 bowel segments and ranged from 0 (no disease) - 60 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to FMD date.
Time frame: Week 52 of study
Percentage of Participants With Corticosteroid-Free Clinical Remission by CDAI at Week 52 Among Participants Receiving Corticosteroids at SS3 Baseline: SS3 Responder Cohort
Corticosteroid-free remission: CDAI score \<150 without receiving corticosteroids for \>=8 weeks prior to Week 52 (for participants receiving corticosteroids at baseline). CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid stools; extent of abdominal pain from 0 (none)-3 (severe); general well-being from 0 (generally well)-4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women; percentage deviation from standard weight, lower bound -10. Total CDAI score=sum of variable scores\*weighting factor and was from 0 (no disease)-600 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Time frame: Week 52 of study
Percentage of Participants With Corticosteroid-Free Clinical Remission by CDAI at Week 52 Among Participants Receiving Corticosteroids at SS3 Baseline: SS3 Non-Responder Cohort
Corticosteroid-free remission: CDAI score \<150 without receiving corticosteroids for \>=8 weeks prior to Week 52 (for participants receiving corticosteroids at baseline). CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid stools; extent of abdominal pain from 0 (none)-3 (severe); general well-being from 0 (generally well)-4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women; percentage deviation from standard weight, lower bound -10. Total CDAI score=sum of variable scores\*weighting factor and was from 0 (no disease)-600 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Time frame: Week 52 of study
Percentage of Participants With Endoscopic Remission at Week 52: SS3 Responder Cohort
Endoscopic remission: SES-CD score \<=4 and at least 2-point reduction from baseline with no sub-score \>1. SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0=none, 1=aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0= none, 1= \<10%, 2= 10% - 30% and 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%, 2= 50% - 75%, and 3= \>75%. Presence of narrowing score: 0=none, 1= single, can be passed, 2=multiple, can be passed, 3= cannot be passed. Total SES CD=sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease.
Time frame: Week 52 of study
Percentage of Participants With Endoscopic Remission at Week 52: SS3 Non-Responder Cohort
Endoscopic remission: SES-CD score \<=4 and at least 2-point reduction from baseline with no sub-score \>1. SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0=none, 1=aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0= none, 1= \<10%, 2= 10% - 30% and 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%, 2= 50% - 75%, and 3= \>75%. Presence of narrowing score: 0=none, 1= single, can be passed, 2=multiple, can be passed, 3= cannot be passed. Total SES CD=sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease.
Time frame: Week 52 of study
Percentage of Participants With Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort
Clinical remission was defined as PRO2 score \<8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
Time frame: Week 52 of study
Percentage of Participants With Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort
Clinical remission was defined as PRO2 score \<8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
Time frame: Week 52 of study
Percentage of Participants With Clinical Response or Endoscopic Response at Week 52: SS3 Responder Cohort
Clinical response: clinical remission CDAI or \>=100-point decrease from baseline in CDAI score where, clinical remission CDAI=CDAI \<150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables. Total CDAI: sum of variable scores\*weighting factor and ranged from 0 (no disease) - 600 (severe disease), higher scores indicated more severe disease. Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from baseline in SES-CD. SES-CD comprised of 4 components assessed for 5 bowel segments. Each component score ranged from 0-3, higher scores indicated more severe condition. Total SES CD: sum of each component score of 5 bowel segments and ranged from 0 (no D) - 60 (severe disease), higher score indicated more severe disease. Percentage of participants with clinical response or endoscopic response at Week 52 is reported.
Time frame: Week 52 of study
Percentage of Participants With Clinical Response or Endoscopic Response at Week 52: SS3 Non-Responder Cohort
Clinical response: clinical remission CDAI or \>=100-point decrease from baseline in CDAI score where, clinical remission CDAI=CDAI \<150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables. Total CDAI: sum of variable scores\*weighting factor and ranged from 0 (no disease) - 600 (severe disease), higher scores indicated more severe disease. Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from baseline in SES-CD. SES-CD comprised of 4 components assessed for 5 bowel segments. Each component score ranged from 0-3, higher scores indicated more severe condition. Total SES CD: sum of each component score of 5 bowel segments and ranged from 0 (no D) - 60 (severe disease), higher score indicated more severe disease. Percentage of participants with clinical response or endoscopic response at Week 52 is reported.
Time frame: Week 52 of study
Change From Baseline in CDAI Score at Weeks 20, 28, 36, 44 and 52: SS3 Responder Cohort
CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Time frame: Baseline, study Weeks 20, 28, 36, 44, 52
Change From Baseline in CDAI Score at Weeks 20, 28, 36, 44 and 52: SS3 Non-Responder Cohort
CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Time frame: Baseline, study Weeks 20, 28, 36, 44, 52
Percentage of Participants With Clinical Response by CDAI at Week 52 Among Participants With Clinical Response by CDAI at SS3 Baseline: SS3 Responder Cohort
Clinical Response was clinical remission by CDAI or \>=100-point decrease from baseline in CDAI score where, clinical remission CDAI= CDAI \<150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none)-3 (severe); general well-being rating assessed from 0 (generally well) - 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide/opiates for diarrhea; presence of an abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score= sum of variable scores\*weighting factor and ranged from 0 (no disease) - 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Time frame: Week 52 of study
Percentage of Participants With Clinical Response by CDAI at Week 52 Among Participants With Clinical Response by CDAI at SS3 Baseline: SS3 Non-Responder Cohort
Clinical Response was clinical remission by CDAI or \>=100-point decrease from baseline in CDAI score where, clinical remission CDAI= CDAI \<150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none)-3 (severe); general well-being rating assessed from 0 (generally well) - 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide/opiates for diarrhea; presence of an abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score= sum of variable scores\*weighting factor and ranged from 0 (no disease) - 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Time frame: Week 52 of study
Change From Baseline in Crohn's Disease Patient-Reported Outcomes (CD-PRO) Module Scores at Weeks 28 and 52: SS3 Responder Cohort
The CD-PRO was a validated instrument designed to assess the signs, symptoms, and impact of CD through 6 modules: Systemic Symptoms, Coping Strategies, Daily Life Impact, Emotional Impact, Bowel Signs and Symptoms and Functional Symptoms. Each module ranged from 0 to 16, where higher scores indicated more severe disease. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Time frame: Baseline, study Weeks 28 and 52
Change From Baseline in Crohn's Disease Patient-Reported Outcomes (CD-PRO) Module Scores at Weeks 28 and 52: SS3 Non-Responder Cohort
The CD-PRO was a validated instrument designed to assess the signs, symptoms, and impact of CD through 6 modules: Systemic Symptoms, Coping Strategies, Daily Life Impact, Emotional Impact, Bowel Signs and Symptoms and Functional Symptoms. Each module ranged from 0 to 16, where higher scores indicated more severe disease. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Time frame: Baseline, study Weeks 28 and 52
Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) at Weeks 28 and 52: SS3 Responder Cohort
The IBDQ was a validated 32 item questionnaire used to assess health related quality of life in participants with IBD. Response to each of the questions ranged from 1 to 7 where higher scores indicated better quality of life. The total IBDQ scores were calculated as sum of individual item scores and ranged from 32 (very poor health-related quality of life) to 224 (perfect health-related quality of life) where higher scores indicated better quality of life. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Time frame: Baseline, study Weeks 28 and 52
Change From Baseline in IBDQ at Weeks 28 and 52: SS3 Non-Responder Cohort
The IBDQ was a validated 32 item questionnaire used to assess health related quality of life in participants with IBD. Response to each of the questions ranged from 1 to 7 where higher scores indicated better quality of life. The total IBDQ scores were calculated as sum of individual item scores and ranged from 32 (very poor health-related quality of life) to 224 (perfect health-related quality of life) where higher scores indicated better quality of life. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Time frame: Baseline, study Weeks 28 and 52
Change From Baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) at Weeks 28 and 52: SS3 Responder Cohort
The SF-36 was a health-related survey that assessed participant's health status and consisted of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function and vitality. The 8 domains are combined to form 2 component scores mental (MCS) and physical (PCS). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain was scored by summing the individual items and transforming the total SF-36 scores into a 0 to 100 scale with higher scores indicating better health status. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Time frame: Baseline, study Weeks 28 and 52
Change From Baseline in SF-36 at Weeks 28 and 52: SS3 Non-Responder Cohort
The SF-36 was a health-related survey that assessed participant's health status and consisted of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function and vitality. The 8 domains are combined to form 2 component scores MCS and PCS. MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain was scored by summing the individual items and transforming the total SF-36 scores into a 0 to 100 scale with higher scores indicating better health status. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Time frame: Baseline, study Weeks 28 and 52
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Weeks 28 and 52: SS3 Responder Cohort
The FACIT-F was a participant completed questionnaire consisting of 13 items that assess fatigue. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0 = not at all; 1 = a little bit; 2 =somewhat; 3 = quite a bit; 4 = very much). Instrument scoring yielded a total FACIT-F score range from 0 to 52 (negatively worded items were reversed during analysis), with higher scores representing better participant status (less fatigue). SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Time frame: Baseline, study Weeks 28 and 52
Change From Baseline in FACIT-F at Weeks 28 and 52: SS3 Non-Responder Cohort
The FACIT-F was a participant completed questionnaire consisting of 13 items that assess fatigue. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0 = not at all; 1 = a little bit; 2 =somewhat; 3 = quite a bit; 4 = very much). Instrument scoring yielded a total FACIT-F score range from 0 to 52 (negatively worded items were reversed during analysis), with higher scores representing better participant status (less fatigue). SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Time frame: Baseline, study Weeks 28 and 52
Percentage of Participants With Clinical Remission by PRO2 at Week 52 Among Participants With Clinical Remission by PRO2 at SS3 Baseline: SS3 Responder Cohort
Clinical remission was defined as PRO2 score \<8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Time frame: Week 52 of study
Percentage of Participants With Clinical Remission by PRO2 at Week 52 Among Participants With Clinical Remission by PRO2 at Study Entry: SS3 Non-Responder Cohort
Clinical remission was defined as PRO2 score \<8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Time frame: Week 52 of study
Change From Baseline in PRO2 Scores at Weeks 20, 28, 36, 44 and 52: SS3 Responder Cohort
The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Time frame: Baseline, study Weeks 20, 28, 36, 44 and 52
Change From Baseline in PRO2 Scores at Weeks 20, 28, 36, 44 and 52: SS3 Non-Responder Cohort
The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Time frame: Baseline, study Weeks 20, 28, 36, 44 and 52
Time to Remission by PRO2 and FCP Concentrations: SS3 Responder Cohort
Time to remission by PRO2 and FCP concentrations was defined as time to onset of clinical remission by PRO2 and FCP normalization. Clinical remission by PRO2 was defined as PRO2 score \<8. Normalization of FCP was defined as FCP \<=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve remission or discontinued from study were censored at 7 days after last dose of study drug.
Time frame: From first maintenance dose in SS3 until date of clinical remission and FCP normalization or censoring date (maximum up to 42 weeks)
Time to Remission by PRO2 and FCP Concentrations: SS3 Non-Responder Cohort
Time to remission by PRO2 and FCP concentrations was defined as time to onset of clinical remission by PRO2 and FCP normalization. Clinical remission by PRO2 was defined as PRO2 score \<8. Normalization of FCP was defined as FCP \<=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve remission or discontinued from study were censored at 7 days after last dose of study drug.
Time frame: From first maintenance dose in SS3 until date of clinical remission and FCP normalization or censoring date (maximum up to 42 weeks)
Time to Response by PRO2 and FCP Concentrations: SS3 Responder Cohort
Time to response by PRO2 and FCP concentrations: time to onset of PRO2 response and FCP normalization. Clinical response by PRO2: clinical remission by PRO2 or \>= 8-point decrease from baseline in PRO2 score. Clinical remission by PRO2: PRO2 score \<8. Normalization of FCP: FCP \<=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve response or discontinued from study were censored at 7 days after last dose of study drug.
Time frame: From first maintenance dose in SS3 until date of clinical response and FCP normalization or censoring date (maximum up to 42 weeks)
Time to Response by PRO2 and FCP Concentrations: SS3 Non-Responder Cohort
Time to response by PRO2 and FCP concentrations: time to onset of PRO2 response and FCP normalization. Clinical response by PRO2: clinical remission by PRO2 or \>= 8-point decrease from baseline in PRO2 score. Clinical remission by PRO2: PRO2 score \<8. Normalization of FCP: FCP \<=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve response or discontinued from study were censored at 7 days after last dose of study drug.
Time frame: From first maintenance dose in SS3 until date of clinical response and FCP normalization or censoring date (maximum up to 42 weeks)
Change From Baseline in SES-CD Score at Week 52: SS3 Responder Cohort
SES-CD was an endoscopic grading system which consisted of composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0=none, 1= \<10%, 2= 10% - 30% and 3= \>30%. Affected surface score: 0=unaffected segment, 1= \<50%, 2= 50% - 75%, and 3= \>75%. Presence of narrowing score: 0=none, 1=single, can be passed, 2=multiple can be passed, 3=cannot be passed. Total SES CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Time frame: Baseline and Week 52 of study
Change From Baseline in SES-CD Score at Week 52: SS3 Non-Responder Cohort
SES-CD was an endoscopic grading system which consisted of composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0=none, 1= \<10%, 2= 10% - 30% and 3= \>30%. Affected surface score: 0=unaffected segment, 1= \<50%, 2= 50% - 75%, and 3= \>75%. Presence of narrowing score: 0=none, 1=single, can be passed, 2=multiple can be passed, 3=cannot be passed. Total SES CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Time frame: Baseline and Week 52 of study
Percentage of Participants With Endoscopic Response and Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort
Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD had 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores=more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0-60, higher score=more severe disease. Clinical remission by PRO2: PRO2 score \<8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. Abdominal pain graded from 0 (none)-3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score calculated as sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. PRO2 score had minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.
Time frame: Week 52 of study
Percentage of Participants With Endoscopic Response and Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort
Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD had 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores=more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0-60, higher score=more severe disease. Clinical remission by PRO2: PRO2 score \<8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. Abdominal pain graded from 0 (none)-3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score calculated as sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. PRO2 score had minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.
Time frame: Week 52 of study
Percentage of Participants With Endoscopic Remission and Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort
Endoscopic remission: SES-CD \<=4 and at least 2-point reduction from baseline with no sub-score \>1. SES-CD comprised of 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores indicated more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0 to 60, higher score indicated more severe disease. Clinical remission by PRO2 was defined as PRO2 score \<8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. PRO2 score had a minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.
Time frame: Week 52 of study
Percentage of Participants With Endoscopic Remission and Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort
Endoscopic remission: SES-CD \<=4 and at least 2-point reduction from baseline with no sub-score \>1. SES-CD comprised of 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores indicated more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0 to 60, higher score indicated more severe disease. Clinical remission by PRO2 was defined as PRO2 score \<8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. PRO2 score had a minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.
Time frame: Week 52 of study
Number of Participants According to Markedly Abnormal Criteria for Electrocardiogram (ECG) Parameters: SS4
Pre-defined markedly abnormal criteria for ECG parameters included: QT interval: \>500 (milliseconds \[msec\]); change from SS4 baseline \>30 msec and change from SS4 baseline \>60 msec. QT interval corrected using Fridericia's formula (QTcF) (msec): \>=450 (male) or \>=470 (female) msec; change from SS4 baseline \>30 msec; change from SS4 baseline \>60 msec. PR interval (msec): \>230 msec. Only those ECG parameters in which at least 1 participant in any of the reporting arm had markedly abnormal criteria are reported in this outcome measure. SS4 Baseline was defined as the last non-missing measurement taken up to the date of first dose in the SS4.
Time frame: Baseline, Weeks 52, and 104 of SS4
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), TEAEs by Severity and Treatment Related TEAEs: SS3
AE: any untoward medical occurrence that did not necessarily have a causal relationship with treatment. SAE: an AE that met one of the following criteria: resulted in death; was life-threatening; required inpatient or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect or medically significant. AEs were graded by the National Cancer Institute Common Terminology Criteria for AE version 5 where, Grade(G) 1: mild AE; G2: moderate; G3: severe; G4: life-threatening consequences, urgent intervention indicated; G5: death related to AE. AE was considered TEAE if it started or worsened in severity on or after the first dose of study treatment. Treatment related AEs were AEs that were related to the study treatment and relatedness was judged by investigator.
Time frame: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
Number of Participants With TEAEs of Special Interest: SS3
The TEAEs of special interest included: cardiovascular events (bradycardia, atrioventricular \[AV\] conduction delay, and hypertension); macular edema; pulmonary disorders (airflow obstruction \[forced expiratory volume in 1 second, and forced vital capacity\], decreased gas exchange \[diffusing capacity of the lung for carbon monoxide\]); infections (severe infections, opportunistic infections, and herpes simplex and herpes zoster); liver injury (liver transaminases elevation, and bilirubin elevation); posterior reversible encephalopathy syndrome; and malignancies. Number of participants with any TEAEs of special interest were reported in this outcome measure.
Time frame: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
Number of Participants With Clinically Meaningful Changes in Laboratory Parameters: SS3
Clinically meaningful laboratory abnormalities:Hemoglobin, Hematocrit, Erythrocytes (\<0.8\*LLN); Ery. Volume, Hemoglobin,Mean Corpuscular HGB Concentration \<0.8\*LLN or \>1.5\*LLN;Reticulocytes, Leukocytes, Lymphocytes, Neutrophils, Neutrophils, Basophils, Eosinophils, Monocytes (\>1.2\*ULN), Prothrombin Time(\>1.1\*ULN).Clinical Chemistry: Bilirubin, Direct Bilirubin, Indirect Bilirubin (1.5\*ULN), Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase (\>3.0\*ULN); Albumin, Urate (\<0.8\*LLN and \>1.2\*ULN; Urea Nitrogen,Creatinine Cholesterol \>1.3\*ULN; Cholesterol \<0.8\*LLN or \>1.2\*LLN, Triglycerides,Potassium,Calcium \< 0.9x LLN \& \>1.1x ULN; Bicarbonate, Glucose, Creatine Kinase. Urinalysis: Glucose, Ketones, Protein, Hemoglobin, Urobilinogen, Bilirubin, Nitrite \>=1; Leukocyte Erythrocytes, Leukocytes \>=20; Epithelial Cells\>=6, Hyaline Cast\>1; Bacteria\>20. Number of participants with any laboratory abnormality meeting specified criteria is included.
Time frame: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
Number of Participants With TEAEs, SAEs, TEAEs by Severity and Treatment Related TEAEs: SS4
AE: any untoward medical occurrence that did not necessarily have a causal relationship with treatment. SAE: an AE that met one of the following criteria: resulted in death; was life-threatening; required inpatient or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect or medically significant. AEs were graded by the National Cancer Institute Common Terminology Criteria for AE version 5 where, G1: mild AE; G2: moderate; G3: severe; G4: life-threatening consequences, urgent intervention indicated; G5: death related to AE. AE was considered TEAE if it started or worsened in severity on or after the first dose of study treatment. Treatment related AEs were AEs that were related to the study treatment and relatedness was judged by investigator.
Time frame: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
Number of Participants With TEAEs of Special Interest: SS4
The TEAEs of special interest included: cardiovascular events (bradycardia, AV conduction delay, and hypertension); macular edema; pulmonary disorders (airflow obstruction \[forced expiratory volume in 1 second, and forced vital capacity\], decreased gas exchange \[diffusing capacity of the lung for carbon monoxide\]); infections (severe infections, opportunistic infections, and herpes simplex and herpes zoster); liver injury (liver transaminases elevation, and bilirubin elevation); posterior reversible encephalopathy syndrome; and malignancies. Number of participants with any TEAEs of special interest were reported in this outcome measure.
Time frame: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
Number of Participants With Clinically Meaningful Changes in Laboratory Parameters: SS4
Clinically meaningful laboratory abnormalities:Hemoglobin, Hematocrit, Erythrocytes (\<0.8\*LLN); Ery. Volume, Hemoglobin,Mean Corpuscular HGB Concentration \<0.8\*LLN or \>1.5\*LLN;Reticulocytes, Leukocytes, Lymphocytes, Neutrophils, Neutrophils, Basophils, Eosinophils, Monocytes (\>1.2\*ULN), Prothrombin Time(\>1.1\*ULN).Clinical Chemistry: Bilirubin, Direct Bilirubin, Indirect Bilirubin (1.5\*ULN), Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase (\>3.0\*ULN); Albumin, Urate (\<0.8\*LLN and \>1.2\*ULN; Urea Nitrogen,Creatinine Cholesterol \>1.3\*ULN; Cholesterol \<0.8\*LLN or \>1.2\*LLN, Triglycerides,Potassium,Calcium \< 0.9x LLN \& \>1.1x ULN; Bicarbonate, Glucose, Creatine Kinase. Urinalysis: Glucose, Ketones, Protein, Hemoglobin, Urobilinogen, Bilirubin, Nitrite \>=1; Leukocyte Erythrocytes, Leukocytes \>=20; Epithelial Cells\>=6, Hyaline Cast\>1; Bacteria\>20. Number of participants with any laboratory abnormality meeting specified criteria is included.
Time frame: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
Number of Participants According to Markedly Abnormal Criteria for Vital Signs: SS4
Pre-defined markedly abnormal criteria for vital signs included: Systolic blood pressure (millimeters of mercury \[mmHg\]): low: \<=90 mmHg and high: \>150 mmHg. Diastolic blood pressure (mmHg): low: \<=50 mmHg and high: \>90 mmHg. Heart rate (beats per minute \[bpm\]): low: \<40 bpm, \<50 bpm and high: \>100 bpm. Only those vital signs parameters in which at least 1 participant in any of the reporting arm had markedly abnormal criteria are reported in this outcome measure. SS4 baseline=the last non-missing measurement taken up to the date of first dose in the SS4.
Time frame: Baseline, Weeks 1, 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Percentage of Participants With Clinical Remission by CDAI at Weeks 12, 24, 36, 52, 64, 76, 88 and 104: SS4
Clinical remission was considered as CDAI score \<150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Time frame: Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Percentage of Participants With Clinical Response by CDAI at Weeks 12, 24, 36, 52, 64, 76, 88 and 104: SS4
Clinical Response was defined as having clinical remission CDAI or \>=100-point decrease from baseline in CDAI score where, clinical remission was considered as CDAI \<150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Time frame: Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Percentage of Participants With Clinical Remission by PRO2 at Weeks 12, 24, 36, 52, 64, 76, 88 and 104: SS4
Clinical remission was defined as PRO2 score \<8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
Time frame: Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
379 participants (84 in sub-study A \[SSA\]; 295 in SS1) enrolled. Participants who completed treatment and met study specific criteria in SS1 eligible for SS3. Participants from SS3 and SSA who completed at least 52 and 66 weeks of treatment, respectively eligible for SS4. Sub-studies planned: SSA, SS1, SS2, SS3 and SS4. The study (including SS3 and SS4) terminated early due to insufficient induction treatment benefit of etrasimod as observed in SS1. SS2 not initiated; its results not reported.
| Milestone | SSA: Placebo in Induction Period | SSA: Etrasimod 2 mg in Induction Period | SSA: Etrasimod 3 mg in Induction Period | SSA: Placebo in Induction Period/Etrasimod 3 mg in Extension Period | SSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension Period | SSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension Period | SSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension Period | SS1: Placebo in Induction Period | SS1: Etrasimod 2 mg in Induction Period | SS1: Etrasimod 3 mg in Induction Period | SS1: Placebo in Induction Period/Etrasimod 2 mg in Extended Induction Period | SS1: Placebo in Induction Period/Etrasimod 3 mg in Extended Induction Period | SS1: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extended Induction Period | SS1: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extended Induction Period | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg | SS4: Etrasimod 2 mg | SS4: Etrasimod 3 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 42 | 41 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 1 | 32 | 36 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 10 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 4 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Disease worsening | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | SSA: Placebo in Induction Period | SSA: Etrasimod 2 mg in Induction Period | SSA: Etrasimod 3 mg in Induction Period | SSA: Placebo in Induction Period/Etrasimod 3 mg in Extension Period | SSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension Period | SSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension Period | SSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension Period | SS1: Placebo in Induction Period | SS1: Etrasimod 2 mg in Induction Period | SS1: Etrasimod 3 mg in Induction Period | SS1: Placebo in Induction Period/Etrasimod 2 mg in Extended Induction Period | SS1: Placebo in Induction Period/Etrasimod 3 mg in Extended Induction Period | SS1: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extended Induction Period | SS1: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extended Induction Period | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg | SS4: Etrasimod 2 mg | SS4: Etrasimod 3 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 1 | 28 | 2 | 34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 1 | 15 | 1 | 21 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 13 | 1 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 3 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 5 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 3 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Disease worsening | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | SSA: Placebo in Induction Period | SSA: Etrasimod 2 mg in Induction Period | SSA: Etrasimod 3 mg in Induction Period | SSA: Placebo in Induction Period/Etrasimod 3 mg in Extension Period | SSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension Period | SSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension Period | SSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension Period | SS1: Placebo in Induction Period | SS1: Etrasimod 2 mg in Induction Period | SS1: Etrasimod 3 mg in Induction Period | SS1: Placebo in Induction Period/Etrasimod 2 mg in Extended Induction Period | SS1: Placebo in Induction Period/Etrasimod 3 mg in Extended Induction Period | SS1: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extended Induction Period | SS1: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extended Induction Period | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg | SS4: Etrasimod 2 mg | SS4: Etrasimod 3 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 98 | 97 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 87 | 89 | 81 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 9 | 16 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 5 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 4 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Disease worsening | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | SSA: Placebo in Induction Period | SSA: Etrasimod 2 mg in Induction Period | SSA: Etrasimod 3 mg in Induction Period | SSA: Placebo in Induction Period/Etrasimod 3 mg in Extension Period | SSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension Period | SSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension Period | SSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension Period | SS1: Placebo in Induction Period | SS1: Etrasimod 2 mg in Induction Period | SS1: Etrasimod 3 mg in Induction Period | SS1: Placebo in Induction Period/Etrasimod 2 mg in Extended Induction Period | SS1: Placebo in Induction Period/Etrasimod 3 mg in Extended Induction Period | SS1: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extended Induction Period | SS1: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extended Induction Period | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg | SS4: Etrasimod 2 mg | SS4: Etrasimod 3 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17 | 18 | 37 | 36 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 15 | 33 | 33 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 4 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Disease worsening | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | SSA: Placebo in Induction Period | SSA: Etrasimod 2 mg in Induction Period | SSA: Etrasimod 3 mg in Induction Period | SSA: Placebo in Induction Period/Etrasimod 3 mg in Extension Period | SSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension Period | SSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension Period | SSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension Period | SS1: Placebo in Induction Period | SS1: Etrasimod 2 mg in Induction Period | SS1: Etrasimod 3 mg in Induction Period | SS1: Placebo in Induction Period/Etrasimod 2 mg in Extended Induction Period | SS1: Placebo in Induction Period/Etrasimod 3 mg in Extended Induction Period | SS1: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extended Induction Period | SS1: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extended Induction Period | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg | SS4: Etrasimod 2 mg | SS4: Etrasimod 3 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 47 | 38 | 33 | 28 | 35 | 15 | 12 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 27 | 29 | 19 | 17 | 21 | 3 | 6 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20 | 9 | 14 | 11 | 14 | 12 | 6 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 2 | 1 | 3 | 2 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 3 | 4 | 2 | 4 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 2 | 0 | 0 |
| Withdrew: Site termination by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 4 | 4 | 4 | 7 | 4 | 1 | 0 | 0 |
| Withdrew: Disease worsening | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 1 | 4 | 1 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | SSA: Placebo in Induction Period | SSA: Etrasimod 2 mg in Induction Period | SSA: Etrasimod 3 mg in Induction Period | SSA: Placebo in Induction Period/Etrasimod 3 mg in Extension Period | SSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension Period | SSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension Period | SSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension Period | SS1: Placebo in Induction Period | SS1: Etrasimod 2 mg in Induction Period | SS1: Etrasimod 3 mg in Induction Period | SS1: Placebo in Induction Period/Etrasimod 2 mg in Extended Induction Period | SS1: Placebo in Induction Period/Etrasimod 3 mg in Extended Induction Period | SS1: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extended Induction Period | SS1: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extended Induction Period | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg | SS4: Etrasimod 2 mg | SS4: Etrasimod 3 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 72 | 71 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 72 | 71 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 5 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Withdrew: Site termination by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 50 | 52 |
| Withdrew: Disease worsening | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 |
Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from study baseline in SES-CD. SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 bowel segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2= large ulcers and 3= very large ulcers. Ulcerated surface score: 0= none, 1= \<10%, 2= 10% - 30% and 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%, 2= 50% - 75%, and 3= \>75%. Presence of narrowing score: 0= none, 1= single, can be passed, 2= multiple, can be passed, 3= cannot be passed. Total SES-CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score indicated more severe disease.
| Percentage of participants | SSA: Placebo in Induction Period | SSA: Etrasimod 2 mg in Induction Period | SSA: Etrasimod 3 mg in Induction Period |
|---|---|---|---|
| Percentage of Participants With Endoscopic Response by Simple Endoscopic Score in Crohn's Disease (SES-CD) at Week 14: SSA | NA (NA to NA) | 21.4 (11.7 to 34.4) | 12.2 (4.9 to 23.9) |
Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from study baseline in SES-CD. SES-CD consisted of composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 bowel segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2= large ulcers and 3= very large ulcers. Ulcerated surface score: 0= none, 1= \<10%, 2= 10% - 30% and 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%, 2= 50% - 75%, and 3= \>75%. Presence of narrowing score: 0= none, 1= single, can be passed, 2= multiple can be passed, 3= cannot be passed. Total SES CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease. Multiple imputation (MI) method used; percentage calculated based on average response rate from MI datasets.
| Percentage of participants | SS1: Placebo in Induction Period | SS1: Etrasimod 2 mg in Induction Period | SS1: Etrasimod 3 mg in Induction Period |
|---|---|---|---|
| Percentage of Participants With Endoscopic Response by SES-CD at Week 14: SS1 | 14.9 (8.8 to 20.9) | 17.3 (10.9 to 23.8) | 14.9 (8.9 to 21.0) |
Clinical remission was considered as CDAI score \<150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); hematocrit (HCT): 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
| Percentage of participants | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo |
|---|---|---|---|---|---|
| Percentage of Participants With Clinical Remission by CDAI at Week 52: SS3 Responder Cohort | 36.4 (17.2 to 59.3) | 69.6 (47.1 to 86.8) | 50.0 (21.1 to 78.9) | 87.5 (61.7 to 98.4) | 73.3 (44.9 to 92.2) |
Clinical remission was considered as CDAI score \<150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
| Percentage of participants | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg |
|---|---|---|
| Percentage of Participants With Clinical Remission by CDAI at Week 52: SS3 Non-Responder Cohort | 0 (0.0 to 70.8) | 60.0 (14.7 to 94.7) |
Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD consisted of composite score based on size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon; rectum. Size of ulcers score: 0=none, 1=aphthous ulcers,2=large ulcers,3=very large ulcers. Ulcerated surface score: 0= none, 1= \<10%, 2= 10% - 30%, 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%,2= 50%-75%,3= \>75%. Presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed,3=cannot be passed. Total SES CD=sum of each domain score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score= more severe disease.
| Percentage of participants | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo |
|---|---|---|---|---|---|
| Percentage of Participants With Endoscopic Response by SES-CD at Week 52: SS3 Responder Cohort | 12.5 (2.7 to 32.4) | 24.0 (9.4 to 45.1) | 10.0 (0.3 to 44.5) | 13.3 (1.7 to 40.5) | 13.3 (1.7 to 40.5) |
Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD consisted of composite score based on size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right, transverse; left colon; rectum. Size of ulcers score: 0=none, 1=aphthous ulcers,2=large ulcers,3=very large ulcers. Ulcerated surface score: 0= none, 1= \<10%, 2= 10% - 30%, 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%,2= 50%-75%,3= \>75%. Presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed,3=cannot be passed. Total SES CD=sum of each domain score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score= more severe disease.
| Percentage of participants | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg |
|---|---|---|
| Percentage of Participants With Endoscopic Response by SES-CD at Week 52: SS3 Non-Responder Cohort | 0 (0.0 to 84.2) | 16.7 (0.4 to 64.1) |
Clinical remission was considered as CDAI score \<150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
| Percentage of participants | SSA: Placebo in Induction Period | SSA: Etrasimod 2 mg in Induction Period | SSA: Etrasimod 3 mg in Induction Period |
|---|---|---|---|
| Percentage of Participants With Clinical Remission by CDAI at Week 14: SSA | NA (NA to NA) | 31.0 (19.4 to 44.6) | 41.5 (28.4 to 55.5) |
SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 bowel segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2= large ulcers and 3= very large ulcers. Ulcerated surface score: 0= none, 1= \<10%, 2= 10% - 30% and 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%, 2= 50% - 75%, and 3= \>75%. Presence of narrowing score: 0= none, 1= single, can be passed, 2= multiple, can be passed, 3= cannot be passed. Total SES-CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score indicated more severe disease.
| Units on a scale | SSA: Placebo in Induction Period | SSA: Etrasimod 2 mg in Induction Period | SSA: Etrasimod 3 mg in Induction Period |
|---|---|---|---|
| Change From Baseline in SES-CD Score at Week 14: SSA | NA ± NA | -1.1 ± 6.63 | -0.9 ± 5.53 |
CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
| Units on a scale | SSA: Placebo in Induction Period | SSA: Etrasimod 2 mg in Induction Period | SSA: Etrasimod 3 mg in Induction Period |
|---|---|---|---|
| Change From Baseline in CDAI Score at Week 14: SSA | NA ± NA | -179.7 ± 92.80 | -136.4 ± 106.38 |
The plasma concentration of etrasimod at 4 hours post-dose has been reported in this outcome measure.
| Nanogram per milliliter | SSA: Etrasimod 2 mg in Induction Period | SSA: Etrasimod 3 mg in Induction Period |
|---|---|---|
| Plasma Concentration of Etrasimod at 4 Hours Post-dose: SSA | 36.32 ± 34.52 | 37.16 ± 32.06 |
The average steady-state Ctrough for Week 2 through 14 was calculated based on individual Ctrough data from Week 2, Week 6 and Week 14.
| Nanogram per milliliter | SSA: Etrasimod 2 mg in Induction Period | SSA: Etrasimod 3 mg in Induction Period |
|---|---|---|
| Steady State Trough Concentration (Ctrough,ss) of Etrasimod From Week 2 to Week 14: SSA | 59.63 ± 42.89 | 82.28 ± 31.38 |
| 10^9 cells per liter | SSA: Placebo in Induction Period | SSA: Etrasimod 2 mg in Induction Period | SSA: Etrasimod 3 mg in Induction Period |
|---|---|---|---|
| Change From Baseline in Absolute Lymphocyte Count (ALC) at Week 14 in Induction Period: SSA | NA ± NA | -1.271 ± 0.7905 | -0.921 ± 0.3825 |
| Percent change | SSA: Placebo in Induction Period | SSA: Etrasimod 2 mg in Induction Period | SSA: Etrasimod 3 mg in Induction Period |
|---|---|---|---|
| Percent Change From Baseline in ALC at Week 14 in Induction Period: SSA | NA ± NA | -60.223 ± 22.7486 | -63.121 ± 13.1499 |
| 10^9 cells per liter | SSA: Placebo in Induction Period/Etrasimod 3 mg in Extension Period | SSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension Period | SSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension Period | SSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension Period |
|---|---|---|---|---|
| Change From Baseline in ALC at Week 66 in Extension Period: SSA | NA ± NA | -1.648 ± 1.1529 | — | -0.931 ± 0.4374 |
| Percent change | SSA: Placebo in Induction Period/Etrasimod 3 mg in Extension Period | SSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension Period | SSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension Period | SSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension Period |
|---|---|---|---|---|
| Percent Change From Baseline in ALC at Week 66 in Extension Period: SSA | NA ± NA | -71.174 ± 10.4559 | — | -60.988 ± 15.2935 |
| Microgram per milligram | SSA: Placebo in Induction Period | SSA: Etrasimod 2 mg in Induction Period | SSA: Etrasimod 3 mg in Induction Period |
|---|---|---|---|
| Change From Baseline in Fecal Calprotectin (FCP) Concentration at Week 14 in Induction Period: SSA | NA ± NA | -19.170 ± 2557.1902 | -1542.684 ± 6282.4409 |
| Percent change | SSA: Placebo in Induction Period | SSA: Etrasimod 2 mg in Induction Period | SSA: Etrasimod 3 mg in Induction Period |
|---|---|---|---|
| Percent Change From Baseline in FCP Concentration at Week 14 in Induction Period: SSA | NA ± NA | 349.591 ± 1556.0649 | 209.156 ± 816.9889 |
| Microgram per milligram | SSA: Placebo in Induction Period/Etrasimod 3 mg in Extension Period | SSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension Period | SSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension Period | SSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension Period |
|---|---|---|---|---|
| Change From Baseline in FCP Concentration at Week 66 in Extension Period: SSA | NA ± NA | -927.343 ± 915.5152 | — | -297.345 ± 982.0333 |
| Percent change | SSA: Placebo in Induction Period/Etrasimod 3 mg in Extension Period | SSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension Period | SSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension Period | SSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension Period |
|---|---|---|---|---|
| Percent Change From Baseline in FCP Concentration at Week 66 in Extension Period: SSA | NA ± NA | -9.613 ± 103.7985 | — | 296.823 ± 812.1047 |
| Milligram per liter | SSA: Placebo in Induction Period | SSA: Etrasimod 2 mg in Induction Period | SSA: Etrasimod 3 mg in Induction Period |
|---|---|---|---|
| Change From Baseline in C-Reactive Protein (CRP) at Week 14 in Induction Period: SSA | NA ± NA | -3.037 ± 22.6182 | -1.459 ± 11.9907 |
| Percent change | SSA: Placebo in Induction Period | SSA: Etrasimod 2 mg in Induction Period | SSA: Etrasimod 3 mg in Induction Period |
|---|---|---|---|
| Percent Change From Baseline in CRP at Week 14 in Induction Period: SSA | NA ± NA | 93.609 ± 232.5276 | 85.476 ± 345.5674 |
| Milligram per liter | SSA: Placebo in Induction Period/Etrasimod 3 mg in Extension Period | SSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension Period | SSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension Period | SSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension Period |
|---|---|---|---|---|
| Change From Baseline in CRP at Week 66 in Extension Period: SSA | NA ± NA | -4.282 ± 21.9909 | — | -3.474 ± 25.6826 |
| Percent change | SSA: Placebo in Induction Period/Etrasimod 3 mg in Extension Period | SSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension Period | SSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension Period | SSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension Period |
|---|---|---|---|---|
| Percent Change From Baseline in CRP at Week 66 in Extension Period: SSA | NA ± NA | -8.856 ± 79.2428 | — | 611.474 ± 1388.2642 |
Clinical remission was considered as CDAI score \<150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease. MI method was used; percentage was calculated based on average response rate from MI datasets.
| Percentage of participants | SS1: Placebo in Induction Period | SS1: Etrasimod 2 mg in Induction Period | SS1: Etrasimod 3 mg in Induction Period |
|---|---|---|---|
| Percentage of Participants With Clinical Remission by CDAI at Week 14: SS1 | 32.0 (24.1 to 39.8) | 29.3 (21.4 to 37.1) | 36.5 (28.3 to 44.7) |
Clinical remission was defined as PRO2 score \<8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. MI method was used; percentage was calculated based on average response rate from MI datasets.
| Percentage of participants | SS1: Placebo in Induction Period | SS1: Etrasimod 2 mg in Induction Period | SS1: Etrasimod 3 mg in Induction Period |
|---|---|---|---|
| Percentage of Participants With Clinical Remission by Patient Reported Outcomes 2 (PRO2) at Week 14: SS1 | 16.2 (10.1 to 22.2) | 27.6 (19.8 to 35.3) | 28.8 (21.0 to 36.6) |
Clinical remission was CDAI score \<150. CDAI was a composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score: sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores= more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
| Percentage of participants | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo |
|---|---|---|---|---|---|
| Percentage of Participants With Clinical Remission by CDAI at Week 52 Among Participants With Clinical Remission by CDAI at SS3 Baseline: SS3 Responder Cohort | 38.5 (13.9 to 68.4) | 92.9 (66.1 to 99.8) | 50.0 (11.8 to 88.2) | 90.9 (58.7 to 99.8) | 100.0 (63.1 to 100.0) |
Clinical remission was CDAI score \<150. CDAI was a composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score: sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores= more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
| Percentage of participants | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg |
|---|---|---|
| Percentage of Participants With Clinical Remission by CDAI at Week 52 Among Participants With Clinical Remission by CDAI at SS3 Baseline: SS3 Non-Responder Cohort | — | 100.0 (2.5 to 100.0) |
Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD= composite score based on 4 components: size of ulcers, ulcerated surface, affected surface, presence of narrowing in 5 segments: ileum; right; transverse; left colon; rectum. Size of ulcers score: 0=none,1= aphthous ulcers, 2= large ulcers, 3= very large ulcers. Ulcerated surface score: 0= none,1= \<10%, 2= 10%-30%, 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%, 2= 50%-75%,3= \>75%. Presence of narrowing score: 0= none,1= single, can be passed, 2= multiple can be passed, 3= can't be passed. Total SES CD=sum of component scores for 5 bowel segments and ranged from 0 (no disease) - 60 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to FMD date.
| Percentage of participants | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo |
|---|---|---|---|---|---|
| Percentage of Participants With Endoscopic Response at Week 52 Among Participants With Endoscopic Response at SS3 Baseline: SS3 Responder Cohort | 60.0 (14.7 to 94.7) | 57.1 (18.4 to 90.1) | 50.0 (1.3 to 98.7) | 50.0 (6.8 to 93.2) | 50.0 (1.3 to 98.7) |
Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD= composite score based on 4 components: size of ulcers, ulcerated surface, affected surface, presence of narrowing in 5 segments: ileum; right; transverse; left colon; rectum. Size of ulcers score: 0=none,1= aphthous ulcers, 2= large ulcers, 3= very large ulcers. Ulcerated surface score: 0= none,1= \<10%, 2= 10%-30%, 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%, 2= 50%-75%,3= \>75%. Presence of narrowing score: 0= none,1= single, can be passed, 2= multiple can be passed, 3= can't be passed. Total SES CD=sum of component scores for 5 bowel segments and ranged from 0 (no disease) - 60 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to FMD date.
No measurements were reported for this outcome.
Corticosteroid-free remission: CDAI score \<150 without receiving corticosteroids for \>=8 weeks prior to Week 52 (for participants receiving corticosteroids at baseline). CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid stools; extent of abdominal pain from 0 (none)-3 (severe); general well-being from 0 (generally well)-4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women; percentage deviation from standard weight, lower bound -10. Total CDAI score=sum of variable scores\*weighting factor and was from 0 (no disease)-600 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
| Percentage of participants | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo |
|---|---|---|---|---|---|
| Percentage of Participants With Corticosteroid-Free Clinical Remission by CDAI at Week 52 Among Participants Receiving Corticosteroids at SS3 Baseline: SS3 Responder Cohort | 28.6 (3.7 to 71.0) | 66.7 (22.3 to 95.7) | 0 (0.0 to 97.5) | 60.0 (14.7 to 94.7) | 66.7 (9.4 to 99.2) |
Corticosteroid-free remission: CDAI score \<150 without receiving corticosteroids for \>=8 weeks prior to Week 52 (for participants receiving corticosteroids at baseline). CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid stools; extent of abdominal pain from 0 (none)-3 (severe); general well-being from 0 (generally well)-4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women; percentage deviation from standard weight, lower bound -10. Total CDAI score=sum of variable scores\*weighting factor and was from 0 (no disease)-600 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
| Percentage of participants | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg |
|---|---|---|
| Percentage of Participants With Corticosteroid-Free Clinical Remission by CDAI at Week 52 Among Participants Receiving Corticosteroids at SS3 Baseline: SS3 Non-Responder Cohort | — | 100.0 (2.5 to 100.0) |
Endoscopic remission: SES-CD score \<=4 and at least 2-point reduction from baseline with no sub-score \>1. SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0=none, 1=aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0= none, 1= \<10%, 2= 10% - 30% and 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%, 2= 50% - 75%, and 3= \>75%. Presence of narrowing score: 0=none, 1= single, can be passed, 2=multiple, can be passed, 3= cannot be passed. Total SES CD=sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease.
| Percentage of participants | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo |
|---|---|---|---|---|---|
| Percentage of Participants With Endoscopic Remission at Week 52: SS3 Responder Cohort | 0 (0.0 to 14.2) | 0 (0.0 to 13.7) | 0 (0.0 to 30.8) | 0 (0.0 to 21.8) | 0 (0.0 to 21.8) |
Endoscopic remission: SES-CD score \<=4 and at least 2-point reduction from baseline with no sub-score \>1. SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0=none, 1=aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0= none, 1= \<10%, 2= 10% - 30% and 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%, 2= 50% - 75%, and 3= \>75%. Presence of narrowing score: 0=none, 1= single, can be passed, 2=multiple, can be passed, 3= cannot be passed. Total SES CD=sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease.
| Percentage of participants | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg |
|---|---|---|
| Percentage of Participants With Endoscopic Remission at Week 52: SS3 Non-Responder Cohort | 0 (0.0 to 84.2) | 0 (0.0 to 45.9) |
Clinical remission was defined as PRO2 score \<8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
| Percentage of participants | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo |
|---|---|---|---|---|---|
| Percentage of Participants With Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort | 27.3 (10.7 to 50.2) | 60.9 (38.5 to 80.3) | 50.0 (21.1 to 78.9) | 62.5 (35.4 to 84.8) | 40.0 (16.3 to 67.7) |
Clinical remission was defined as PRO2 score \<8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
| Percentage of participants | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg |
|---|---|---|
| Percentage of Participants With Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort | 0 (0.0 to 70.8) | 40.0 (5.3 to 85.3) |
Clinical response: clinical remission CDAI or \>=100-point decrease from baseline in CDAI score where, clinical remission CDAI=CDAI \<150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables. Total CDAI: sum of variable scores\*weighting factor and ranged from 0 (no disease) - 600 (severe disease), higher scores indicated more severe disease. Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from baseline in SES-CD. SES-CD comprised of 4 components assessed for 5 bowel segments. Each component score ranged from 0-3, higher scores indicated more severe condition. Total SES CD: sum of each component score of 5 bowel segments and ranged from 0 (no D) - 60 (severe disease), higher score indicated more severe disease. Percentage of participants with clinical response or endoscopic response at Week 52 is reported.
| Percentage of participants | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo |
|---|---|---|---|---|---|
| Percentage of Participants With Clinical Response or Endoscopic Response at Week 52: SS3 Responder Cohort | 70.8 (48.9 to 87.4) | 84.0 (63.9 to 95.5) | 66.7 (34.9 to 90.1) | 93.8 (69.8 to 99.8) | 75.0 (47.6 to 92.7) |
Clinical response: clinical remission CDAI or \>=100-point decrease from baseline in CDAI score where, clinical remission CDAI=CDAI \<150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables. Total CDAI: sum of variable scores\*weighting factor and ranged from 0 (no disease) - 600 (severe disease), higher scores indicated more severe disease. Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from baseline in SES-CD. SES-CD comprised of 4 components assessed for 5 bowel segments. Each component score ranged from 0-3, higher scores indicated more severe condition. Total SES CD: sum of each component score of 5 bowel segments and ranged from 0 (no D) - 60 (severe disease), higher score indicated more severe disease. Percentage of participants with clinical response or endoscopic response at Week 52 is reported.
| Percentage of participants | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg |
|---|---|---|
| Percentage of Participants With Clinical Response or Endoscopic Response at Week 52: SS3 Non-Responder Cohort | 0 (0.0 to 70.8) | 50.0 (11.8 to 88.2) |
CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
| Units on a scale | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo |
|---|---|---|---|---|---|
| Week 20 | 22.8 ± 110.65 | -7.8 ± 85.23 | 29.6 ± 116.36 | 12.3 ± 64.57 | -6.8 ± 74.34 |
| Week 28 | -5.1 ± 77.47 | -33.3 ± 56.26 | 2.5 ± 110.94 | 16.9 ± 67.92 | -17.4 ± 57.51 |
| Week 36 | 6.6 ± 86.81 | -9.1 ± 52.90 | 0.6 ± 111.75 | 10.2 ± 65.61 | -14.0 ± 66.42 |
| Week 44 | 6.0 ± 90.24 | -25.0 ± 77.0 | -24.0 ± 80.95 | -6.5 ± 56.14 | -4.3 ± 67.80 |
| Week 52 | 7.2 ± 83.06 | -30.6 ± 65.99 | -17.6 ± 95.37 | -8.1 ± 60.53 | -7.2 ± 56.05 |
CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
| Units on a scale | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg |
|---|---|---|
| Week 20 | -13.9 ± 64.28 | 4.1 ± 71.53 |
| Week 28 | -14.8 ± 49.59 | -24.8 ± 129.50 |
| Week 36 | -7.7 ± 76.32 | -5.8 ± 56.78 |
| Week 44 | 1.5 ± 94.92 | -30.7 ± 64.30 |
| Week 52 | 16.4 ± 39.97 | -37.1 ± 80.80 |
Clinical Response was clinical remission by CDAI or \>=100-point decrease from baseline in CDAI score where, clinical remission CDAI= CDAI \<150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none)-3 (severe); general well-being rating assessed from 0 (generally well) - 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide/opiates for diarrhea; presence of an abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score= sum of variable scores\*weighting factor and ranged from 0 (no disease) - 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
| Percentage of participants | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo |
|---|---|---|---|---|---|
| Percentage of Participants With Clinical Response by CDAI at Week 52 Among Participants With Clinical Response by CDAI at SS3 Baseline: SS3 Responder Cohort | 75.0 (50.90 to 91.34) | 89.5 (66.86 to 98.70) | 66.7 (29.93 to 92.51) | 92.9 (66.13 to 99.82) | 100.0 (69.15 to 100.00) |
Clinical Response was clinical remission by CDAI or \>=100-point decrease from baseline in CDAI score where, clinical remission CDAI= CDAI \<150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none)-3 (severe); general well-being rating assessed from 0 (generally well) - 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide/opiates for diarrhea; presence of an abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score= sum of variable scores\*weighting factor and ranged from 0 (no disease) - 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
| Percentage of participants | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg |
|---|---|---|
| Percentage of Participants With Clinical Response by CDAI at Week 52 Among Participants With Clinical Response by CDAI at SS3 Baseline: SS3 Non-Responder Cohort | — | 100.0 (2.50 to 100.00) |
The CD-PRO was a validated instrument designed to assess the signs, symptoms, and impact of CD through 6 modules: Systemic Symptoms, Coping Strategies, Daily Life Impact, Emotional Impact, Bowel Signs and Symptoms and Functional Symptoms. Each module ranged from 0 to 16, where higher scores indicated more severe disease. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
| Units on a scale | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo |
|---|---|---|---|---|---|
| Systemic Symptoms: Week 28 | -0.2 ± 0.67 | -0.1 ± 0.41 | 0.0 ± 0.96 | -0.1 ± 0.47 | -0.3 ± 0.87 |
| Systemic Symptoms: Week 52 | -0.3 ± 0.61 | 0.0 ± 0.54 | 0.0 ± 0.67 | -0.3 ± 0.60 | -0.5 ± 0.87 |
| Coping Strategies: Week 28 | -0.4 ± 1.34 | -0.3 ± 1.19 | -0.3 ± 1.27 | -0.3 ± 1.08 | -0.2 ± 1.97 |
| Coping Strategies: Week 52 | -0.5 ± 1.62 | 0.0 ± 1.54 | -0.2 ± 0.96 | -0.4 ± 1.08 | -0.4 ± 2.20 |
| Daily Life Impact: Week 28 | -0.3 ± 0.79 | -0.2 ± 0.71 | 0.3 ± 0.95 | -0.1 ± 0.91 | 0.0 ± 0.96 |
| Daily Life Impact: Week 52 | 0.0 ± 0.97 | 0.1 ± 0.82 | 0.6 ± 0.72 | -0.2 ± 0.96 | -0.5 ± 0.92 |
| Emotional Impact: Week 28 | 0.0 ± 0.78 | 0.0 ± 0.72 | 0.2 ± 0.97 | 0.0 ± 0.66 | -0.1 ± 0.92 |
| Emotional Impact: Week 52 | -0.1 ± 0.90 | 0.2 ± 0.71 | 0.4 ± 0.76 | -0.2 ± 0.53 | -0.5 ± 0.90 |
| Bowel Signs and Symptoms: Week 28 | -0.2 ± 0.63 | -0.2 ± 0.66 | 0.0 ± 0.94 | -0.2 ± 0.80 | -0.3 ± 0.73 |
| Bowel Signs and Symptoms: Week 52 | -0.3 ± 0.97 | 0.1 ± 0.71 | 0.2 ± 0.66 | -0.2 ± 0.99 | -0.5 ± 0.82 |
| Functional Symptoms: Week 28 | -0.2 ± 0.71 | -0.1 ± 0.45 | -0.2 ± 0.94 | 0.1 ± 0.36 | -0.3 ± 0.74 |
| Functional Symptoms: Week 52 | -0.3 ± 0.63 | -0.1 ± 0.48 | -0.1 ± 0.53 | -0.2 ± 0.44 | -0.7 ± 1.31 |
The CD-PRO was a validated instrument designed to assess the signs, symptoms, and impact of CD through 6 modules: Systemic Symptoms, Coping Strategies, Daily Life Impact, Emotional Impact, Bowel Signs and Symptoms and Functional Symptoms. Each module ranged from 0 to 16, where higher scores indicated more severe disease. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
| Units on a scale | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg |
|---|---|---|
| Systemic Symptoms: Week 28 | 0.0 ± 0.35 | 0.1 ± 0.43 |
| Systemic Symptoms: Week 52 | 0.4 ± 0.56 | 0.0 ± 0.07 |
| Coping Strategies: Week 28 | 0.0 ± 1.09 | 0.3 ± 0.52 |
| Coping Strategies: Week 52 | 0.4 ± 2.49 | 0.1 ± 0.26 |
| Daily Life Impact: Week 28 | 0.1 ± 0.71 | 0.0 ± 0.49 |
| Daily Life Impact: Week 52 | -0.1 ± 0.75 | 0.1 ± 0.58 |
| Emotional Impact: Week 28 | -0.1 ± 0.91 | 0.2 ± 0.31 |
| Emotional Impact: Week 52 | 0.6 ± 1.15 | 0.1 ± 0.71 |
| Bowel Signs and Symptoms: Week 28 | -0.3 ± 0.85 | -0.1 ± 1.22 |
| Bowel Signs and Symptoms: Week 52 | -0.1 ± 1.29 | -0.2 ± 0.23 |
| Functional Symptoms: Week 28 | 0.0 ± 0.28 | 0.1 ± 0.60 |
| Functional Symptoms: Week 52 | -0.2 ± 0.12 | -0.4 ± 0.33 |
The IBDQ was a validated 32 item questionnaire used to assess health related quality of life in participants with IBD. Response to each of the questions ranged from 1 to 7 where higher scores indicated better quality of life. The total IBDQ scores were calculated as sum of individual item scores and ranged from 32 (very poor health-related quality of life) to 224 (perfect health-related quality of life) where higher scores indicated better quality of life. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
| Units on a scale | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo |
|---|---|---|---|---|---|
| Week 28 | 2.7 ± 32.18 | 0.2 ± 22.67 | -5.4 ± 37.06 | 3.7 ± 31.22 | -3.2 ± 28.55 |
| Week 52 | -0.9 ± 37.99 | -5.7 ± 32.07 | -12.1 ± 39.21 | 8.8 ± 32.79 | 0.6 ± 21.32 |
The IBDQ was a validated 32 item questionnaire used to assess health related quality of life in participants with IBD. Response to each of the questions ranged from 1 to 7 where higher scores indicated better quality of life. The total IBDQ scores were calculated as sum of individual item scores and ranged from 32 (very poor health-related quality of life) to 224 (perfect health-related quality of life) where higher scores indicated better quality of life. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
| Units on a scale | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg |
|---|---|---|
| Week 28 | -0.3 ± 32.45 | -4.9 ± 17.07 |
| Week 52 | 1.5 ± 23.33 | 4.0 ± 15.26 |
The SF-36 was a health-related survey that assessed participant's health status and consisted of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function and vitality. The 8 domains are combined to form 2 component scores mental (MCS) and physical (PCS). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain was scored by summing the individual items and transforming the total SF-36 scores into a 0 to 100 scale with higher scores indicating better health status. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
| Units on a scale | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo |
|---|---|---|---|---|---|
| Week 28 | 0.0 ± 0.11 | 0.0 ± 0.08 | 0.0 ± 0.12 | 0.0 ± 0.08 | 0.0 ± 0.12 |
| Week 52 | 0.0 ± 0.15 | 0.0 ± 0.12 | 0.0 ± 0.07 | 0.0 ± 0.12 | 0.0 ± 0.09 |
The SF-36 was a health-related survey that assessed participant's health status and consisted of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function and vitality. The 8 domains are combined to form 2 component scores MCS and PCS. MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain was scored by summing the individual items and transforming the total SF-36 scores into a 0 to 100 scale with higher scores indicating better health status. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
| Units on a scale | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg |
|---|---|---|
| Week 28 | 0.0 ± 0.10 | 0.0 ± 0.06 |
| Week 52 | 0.0 ± 0.19 | 0.0 ± 0.10 |
The FACIT-F was a participant completed questionnaire consisting of 13 items that assess fatigue. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0 = not at all; 1 = a little bit; 2 =somewhat; 3 = quite a bit; 4 = very much). Instrument scoring yielded a total FACIT-F score range from 0 to 52 (negatively worded items were reversed during analysis), with higher scores representing better participant status (less fatigue). SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
| Units on a scale | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo |
|---|---|---|---|---|---|
| Week 28 | 0.3 ± 9.66 | 0.4 ± 10.07 | -3.4 ± 11.52 | 0.0 ± 9.54 | 0.7 ± 7.98 |
| Week 52 | -1.9 ± 13.56 | -1.4 ± 8.94 | -1.8 ± 8.64 | 0.0 ± 12.83 | 1.7 ± 7.48 |
The FACIT-F was a participant completed questionnaire consisting of 13 items that assess fatigue. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0 = not at all; 1 = a little bit; 2 =somewhat; 3 = quite a bit; 4 = very much). Instrument scoring yielded a total FACIT-F score range from 0 to 52 (negatively worded items were reversed during analysis), with higher scores representing better participant status (less fatigue). SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
| Units on a scale | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg |
|---|---|---|
| Week 28 | -0.6 ± 12.32 | -0.3 ± 5.44 |
| Week 52 | -3.0 ± 12.29 | 1.5 ± 2.07 |
Clinical remission was defined as PRO2 score \<8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
| Percentage of participants | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo |
|---|---|---|---|---|---|
| Percentage of Participants With Clinical Remission by PRO2 at Week 52 Among Participants With Clinical Remission by PRO2 at SS3 Baseline: SS3 Responder Cohort | 66.7 (9.43 to 99.16) | 90.0 (55.50 to 99.75) | 60.0 (14.66 to 94.73) | 77.8 (39.99 to 97.19) | 71.4 (29.04 to 96.33) |
Clinical remission was defined as PRO2 score \<8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
| Percentage of participants | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg |
|---|---|---|
| Percentage of Participants With Clinical Remission by PRO2 at Week 52 Among Participants With Clinical Remission by PRO2 at Study Entry: SS3 Non-Responder Cohort | — | 100.0 (2.50 to 100.00) |
The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
| Units on a scale | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo |
|---|---|---|---|---|---|
| Week 20 | 0.6 ± 2.83 | 0.2 ± 2.59 | 0.6 ± 2.44 | 0.1 ± 1.50 | 0.2 ± 2.27 |
| Week 28 | -0.5 ± 1.84 | -0.6 ± 1.75 | -0.2 ± 2.16 | 0.2 ± 1.79 | -0.3 ± 1.26 |
| Week 36 | -0.2 ± 2.12 | -0.1 ± 1.42 | 0.0 ± 2.86 | 0.0 ± 1.75 | -0.2 ± 1.60 |
| Week 44 | -0.3 ± 1.72 | -0.4 ± 2.49 | -0.7 ± 1.97 | -0.1 ± 1.86 | -0.3 ± 1.79 |
| Week 52 | 0.2 ± 1.72 | -0.5 ± 2.08 | -0.7 ± 2.27 | -0.2 ± 1.59 | -0.3 ± 1.47 |
The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
| Units on a scale | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg |
|---|---|---|
| Week 20 | 0.2 ± 2.11 | -0.5 ± 2.48 |
| Week 28 | -0.7 ± 1.80 | -1.6 ± 4.45 |
| Week 36 | -0.7 ± 2.18 | -0.8 ± 1.22 |
| Week 44 | -0.1 ± 3.52 | -1.3 ± 1.14 |
| Week 52 | 0.1 ± 0.81 | -1.3 ± 1.31 |
Time to remission by PRO2 and FCP concentrations was defined as time to onset of clinical remission by PRO2 and FCP normalization. Clinical remission by PRO2 was defined as PRO2 score \<8. Normalization of FCP was defined as FCP \<=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve remission or discontinued from study were censored at 7 days after last dose of study drug.
| Days | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo |
|---|---|---|---|---|---|
| Time to Remission by PRO2 and FCP Concentrations: SS3 Responder Cohort | 189.7 ± 94.8 | 200.1 ± 105.3 | 153.5 ± 101.9 | 161.2 ± 121.6 | 154.1 ± 111.3 |
Time to remission by PRO2 and FCP concentrations was defined as time to onset of clinical remission by PRO2 and FCP normalization. Clinical remission by PRO2 was defined as PRO2 score \<8. Normalization of FCP was defined as FCP \<=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve remission or discontinued from study were censored at 7 days after last dose of study drug.
| Days | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg |
|---|---|---|
| Time to Remission by PRO2 and FCP Concentrations: SS3 Non-Responder Cohort | 158.7 ± 70.4 | 157.7 ± 108.7 |
Time to response by PRO2 and FCP concentrations: time to onset of PRO2 response and FCP normalization. Clinical response by PRO2: clinical remission by PRO2 or \>= 8-point decrease from baseline in PRO2 score. Clinical remission by PRO2: PRO2 score \<8. Normalization of FCP: FCP \<=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve response or discontinued from study were censored at 7 days after last dose of study drug.
| Days | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo |
|---|---|---|---|---|---|
| Time to Response by PRO2 and FCP Concentrations: SS3 Responder Cohort | 189.7 ± 94.8 | 200.1 ± 105.3 | 153.5 ± 101.9 | 161.2 ± 121.6 | 154.1 ± 111.3 |
Time to response by PRO2 and FCP concentrations: time to onset of PRO2 response and FCP normalization. Clinical response by PRO2: clinical remission by PRO2 or \>= 8-point decrease from baseline in PRO2 score. Clinical remission by PRO2: PRO2 score \<8. Normalization of FCP: FCP \<=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve response or discontinued from study were censored at 7 days after last dose of study drug.
| Days | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg |
|---|---|---|
| Time to Response by PRO2 and FCP Concentrations: SS3 Non-Responder Cohort | 158.7 ± 70.4 | 152.7 ± 110.0 |
SES-CD was an endoscopic grading system which consisted of composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0=none, 1= \<10%, 2= 10% - 30% and 3= \>30%. Affected surface score: 0=unaffected segment, 1= \<50%, 2= 50% - 75%, and 3= \>75%. Presence of narrowing score: 0=none, 1=single, can be passed, 2=multiple can be passed, 3=cannot be passed. Total SES CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
| Units on a scale | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo |
|---|---|---|---|---|---|
| Change From Baseline in SES-CD Score at Week 52: SS3 Responder Cohort | 1.3 ± 5.98 | -0.3 ± 4.72 | 0.4 ± 5.68 | 0.6 ± 3.81 | -2.1 ± 5.94 |
SES-CD was an endoscopic grading system which consisted of composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0=none, 1= \<10%, 2= 10% - 30% and 3= \>30%. Affected surface score: 0=unaffected segment, 1= \<50%, 2= 50% - 75%, and 3= \>75%. Presence of narrowing score: 0=none, 1=single, can be passed, 2=multiple can be passed, 3=cannot be passed. Total SES CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
| Units on a scale | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg |
|---|---|---|
| Change From Baseline in SES-CD Score at Week 52: SS3 Non-Responder Cohort | 8.5 ± 3.54 | 1.7 ± 4.37 |
Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD had 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores=more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0-60, higher score=more severe disease. Clinical remission by PRO2: PRO2 score \<8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. Abdominal pain graded from 0 (none)-3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score calculated as sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. PRO2 score had minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.
| Percentage of participants | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo |
|---|---|---|---|---|---|
| Percentage of Participants With Endoscopic Response and Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort | 0.0 (0.00 to 14.82) | 20.0 (6.83 to 40.70) | 0.0 (0.00 to 26.46) | 12.5 (1.55 to 38.35) | 0.0 (0.00 to 20.59) |
Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD had 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores=more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0-60, higher score=more severe disease. Clinical remission by PRO2: PRO2 score \<8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. Abdominal pain graded from 0 (none)-3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score calculated as sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. PRO2 score had minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.
| Percentage of participants | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg |
|---|---|---|
| Percentage of Participants With Endoscopic Response and Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort | 0.0 (0.00 to 70.76) | 0.0 (0.00 to 45.93) |
Endoscopic remission: SES-CD \<=4 and at least 2-point reduction from baseline with no sub-score \>1. SES-CD comprised of 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores indicated more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0 to 60, higher score indicated more severe disease. Clinical remission by PRO2 was defined as PRO2 score \<8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. PRO2 score had a minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.
| Percentage of participants | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo |
|---|---|---|---|---|---|
| Percentage of Participants With Endoscopic Remission and Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort | 0.0 (0.00 to 14.25) | 0.0 (0.00 to 13.72) | 0.0 (0.00 to 26.46) | 0.0 (0.00 to 20.59) | 0.0 (0.00 to 20.59) |
Endoscopic remission: SES-CD \<=4 and at least 2-point reduction from baseline with no sub-score \>1. SES-CD comprised of 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores indicated more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0 to 60, higher score indicated more severe disease. Clinical remission by PRO2 was defined as PRO2 score \<8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. PRO2 score had a minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.
| Percentage of participants | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg |
|---|---|---|
| Percentage of Participants With Endoscopic Remission and Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort | 0.0 (0.00 to 70.76) | 0.0 (0.00 to 45.93) |
Pre-defined markedly abnormal criteria for ECG parameters included: QT interval: \>500 (milliseconds \[msec\]); change from SS4 baseline \>30 msec and change from SS4 baseline \>60 msec. QT interval corrected using Fridericia's formula (QTcF) (msec): \>=450 (male) or \>=470 (female) msec; change from SS4 baseline \>30 msec; change from SS4 baseline \>60 msec. PR interval (msec): \>230 msec. Only those ECG parameters in which at least 1 participant in any of the reporting arm had markedly abnormal criteria are reported in this outcome measure. SS4 Baseline was defined as the last non-missing measurement taken up to the date of first dose in the SS4.
| Participants | SS4: Etrasimod 2 mg | SS4: Etrasimod 3 mg |
|---|---|---|
| Baseline; QTcF Interval: >=450 (male) or >=470 (female) msec | 1 | 0 |
| Week 52; QTcF Interval: >=450 (male) or >=470 (female) msec | 3 | 1 |
| Week 52; QTcF Interval: change from baseline >30 msec | 2 | 1 |
| Week 104; QTcF Interval: >=450 (male) or >=470 (female) msec | 1 | 1 |
| Week 104; QTcF Interval: change from baseline >30 msec | 3 | 1 |
AE: any untoward medical occurrence that did not necessarily have a causal relationship with treatment. SAE: an AE that met one of the following criteria: resulted in death; was life-threatening; required inpatient or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect or medically significant. AEs were graded by the National Cancer Institute Common Terminology Criteria for AE version 5 where, Grade(G) 1: mild AE; G2: moderate; G3: severe; G4: life-threatening consequences, urgent intervention indicated; G5: death related to AE. AE was considered TEAE if it started or worsened in severity on or after the first dose of study treatment. Treatment related AEs were AEs that were related to the study treatment and relatedness was judged by investigator.
| Participants | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg |
|---|---|---|---|---|---|---|---|
| Participants with TEAE | 35 | 30 | 27 | 25 | 23 | 26 | 18 |
| Participants with SAE | 2 | 4 | 3 | 6 | 4 | 5 | 4 |
| Participants with Grade 1 TEAE | 11 | 11 | 12 | 10 | 12 | 7 | 9 |
| Participants with Grade 2 TEAE | 18 | 14 | 10 | 13 | 7 | 15 | 5 |
| Participants with Grade 3 TEAE | 6 | 4 | 5 | 2 | 4 | 4 | 4 |
| Participants with Grade 4 TEAE | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Participants with Grade 5 TEAE | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants with Treatment Related TEAE | 4 | 10 | 4 | 8 | 2 | 8 | 6 |
The TEAEs of special interest included: cardiovascular events (bradycardia, atrioventricular \[AV\] conduction delay, and hypertension); macular edema; pulmonary disorders (airflow obstruction \[forced expiratory volume in 1 second, and forced vital capacity\], decreased gas exchange \[diffusing capacity of the lung for carbon monoxide\]); infections (severe infections, opportunistic infections, and herpes simplex and herpes zoster); liver injury (liver transaminases elevation, and bilirubin elevation); posterior reversible encephalopathy syndrome; and malignancies. Number of participants with any TEAEs of special interest were reported in this outcome measure.
| Participants | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg |
|---|---|---|---|---|---|---|---|
| Number of Participants With TEAEs of Special Interest: SS3 | 0 | 4 | 0 | 4 | 2 | 1 | 5 |
Clinically meaningful laboratory abnormalities:Hemoglobin, Hematocrit, Erythrocytes (\<0.8\*LLN); Ery. Volume, Hemoglobin,Mean Corpuscular HGB Concentration \<0.8\*LLN or \>1.5\*LLN;Reticulocytes, Leukocytes, Lymphocytes, Neutrophils, Neutrophils, Basophils, Eosinophils, Monocytes (\>1.2\*ULN), Prothrombin Time(\>1.1\*ULN).Clinical Chemistry: Bilirubin, Direct Bilirubin, Indirect Bilirubin (1.5\*ULN), Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase (\>3.0\*ULN); Albumin, Urate (\<0.8\*LLN and \>1.2\*ULN; Urea Nitrogen,Creatinine Cholesterol \>1.3\*ULN; Cholesterol \<0.8\*LLN or \>1.2\*LLN, Triglycerides,Potassium,Calcium \< 0.9x LLN \& \>1.1x ULN; Bicarbonate, Glucose, Creatine Kinase. Urinalysis: Glucose, Ketones, Protein, Hemoglobin, Urobilinogen, Bilirubin, Nitrite \>=1; Leukocyte Erythrocytes, Leukocytes \>=20; Epithelial Cells\>=6, Hyaline Cast\>1; Bacteria\>20. Number of participants with any laboratory abnormality meeting specified criteria is included.
| Participants | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg |
|---|---|---|---|---|---|---|---|
| Number of Participants With Clinically Meaningful Changes in Laboratory Parameters: SS3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AE: any untoward medical occurrence that did not necessarily have a causal relationship with treatment. SAE: an AE that met one of the following criteria: resulted in death; was life-threatening; required inpatient or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect or medically significant. AEs were graded by the National Cancer Institute Common Terminology Criteria for AE version 5 where, G1: mild AE; G2: moderate; G3: severe; G4: life-threatening consequences, urgent intervention indicated; G5: death related to AE. AE was considered TEAE if it started or worsened in severity on or after the first dose of study treatment. Treatment related AEs were AEs that were related to the study treatment and relatedness was judged by investigator.
| Participants | SS4: Etrasimod 2 mg | SS4: Etrasimod 3 mg |
|---|---|---|
| Participants with TEAEs | 56 | 55 |
| Participants with SAEs | 10 | 8 |
| Participants with Grade 1 AEs | 21 | 25 |
| Participants with Grade 2 AEs | 18 | 23 |
| Participants with Grade 3 AEs | 15 | 6 |
| Participants with Grade 4 AEs | 1 | 1 |
| Participants with Grade 5 AEs | 1 | 0 |
| Participants with Treatment Related AEs | 17 | 22 |
The TEAEs of special interest included: cardiovascular events (bradycardia, AV conduction delay, and hypertension); macular edema; pulmonary disorders (airflow obstruction \[forced expiratory volume in 1 second, and forced vital capacity\], decreased gas exchange \[diffusing capacity of the lung for carbon monoxide\]); infections (severe infections, opportunistic infections, and herpes simplex and herpes zoster); liver injury (liver transaminases elevation, and bilirubin elevation); posterior reversible encephalopathy syndrome; and malignancies. Number of participants with any TEAEs of special interest were reported in this outcome measure.
| Participants | SS4: Etrasimod 2 mg | SS4: Etrasimod 3 mg |
|---|---|---|
| Number of Participants With TEAEs of Special Interest: SS4 | 8 | 5 |
Clinically meaningful laboratory abnormalities:Hemoglobin, Hematocrit, Erythrocytes (\<0.8\*LLN); Ery. Volume, Hemoglobin,Mean Corpuscular HGB Concentration \<0.8\*LLN or \>1.5\*LLN;Reticulocytes, Leukocytes, Lymphocytes, Neutrophils, Neutrophils, Basophils, Eosinophils, Monocytes (\>1.2\*ULN), Prothrombin Time(\>1.1\*ULN).Clinical Chemistry: Bilirubin, Direct Bilirubin, Indirect Bilirubin (1.5\*ULN), Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase (\>3.0\*ULN); Albumin, Urate (\<0.8\*LLN and \>1.2\*ULN; Urea Nitrogen,Creatinine Cholesterol \>1.3\*ULN; Cholesterol \<0.8\*LLN or \>1.2\*LLN, Triglycerides,Potassium,Calcium \< 0.9x LLN \& \>1.1x ULN; Bicarbonate, Glucose, Creatine Kinase. Urinalysis: Glucose, Ketones, Protein, Hemoglobin, Urobilinogen, Bilirubin, Nitrite \>=1; Leukocyte Erythrocytes, Leukocytes \>=20; Epithelial Cells\>=6, Hyaline Cast\>1; Bacteria\>20. Number of participants with any laboratory abnormality meeting specified criteria is included.
| Participants | SS4: Etrasimod 2 mg | SS4: Etrasimod 3 mg |
|---|---|---|
| Number of Participants With Clinically Meaningful Changes in Laboratory Parameters: SS4 | 0 | 0 |
Pre-defined markedly abnormal criteria for vital signs included: Systolic blood pressure (millimeters of mercury \[mmHg\]): low: \<=90 mmHg and high: \>150 mmHg. Diastolic blood pressure (mmHg): low: \<=50 mmHg and high: \>90 mmHg. Heart rate (beats per minute \[bpm\]): low: \<40 bpm, \<50 bpm and high: \>100 bpm. Only those vital signs parameters in which at least 1 participant in any of the reporting arm had markedly abnormal criteria are reported in this outcome measure. SS4 baseline=the last non-missing measurement taken up to the date of first dose in the SS4.
| Participants | SS4: Etrasimod 2 mg | SS4: Etrasimod 3 mg |
|---|---|---|
| Baseline; Systolic Blood Pressure: <=90 mmHg | 1 | 0 |
| Baseline; Systolic Blood Pressure: >150 mmHg | 1 | 2 |
| Baseline; Diastolic Blood Pressure: <=50 mmHg | 1 | 0 |
| Baseline; Diastolic Blood Pressure: >90 mmHg | 6 | 7 |
| Baseline; Heart Rate: >100 bpm | 1 | 0 |
| Week 1; Diastolic Blood Pressure: <=50 mmHg | 2 | 0 |
| Week 1; Diastolic Blood Pressure: >90 mmHg | 0 | 1 |
| Week 12; Systolic Blood Pressure: >150 mmHg | 0 | 2 |
| Week 12; Diastolic Blood Pressure: >90 mmHg | 5 | 9 |
| Week 24; Systolic Blood Pressure: <=90 mmHg | 1 | 0 |
| Week 24; Systolic Blood Pressure: >150 mmHg | 1 | 4 |
| Week 24; Diastolic Blood Pressure: >90 mmHg | 2 | 6 |
| Week 36; Systolic Blood Pressure: >150 mmHg | 0 | 2 |
| Week 36; Diastolic Blood Pressure: >90 mmHg | 1 | 3 |
| Week 36; Heart Rate: >100 bpm | 0 | 1 |
| Week 52; Diastolic blood pressure: >90 mmHg | 2 | 1 |
| Week 52; Heart Rate: >100 bpm | 0 | 1 |
| Week 64; Systolic blood pressure: >150 mmHg | 1 | 2 |
| Week 64; Diastolic blood pressure: >90 mmHg | 2 | 2 |
| Week 64; Heart Rate: >100 bpm | 0 | 1 |
| Week 76; Systolic blood pressure: >150 mmHg | 1 | 2 |
| Week 76; Diastolic blood pressure: >90 mmHg | 2 | 1 |
| Week 88; Systolic blood pressure: >150 mmHg | 0 | 1 |
| Week 88; Diastolic blood pressure: >90 mmHg | 1 | 0 |
| Week 88; Heart Rate: >100 bpm | 0 | 1 |
Clinical remission was considered as CDAI score \<150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
| Percentage of participants | SS4: Etrasimod 2 mg | SS4: Etrasimod 3 mg |
|---|---|---|
| Week 12 | 71.7 (57.7 to 83.2) | 64.9 (51.1 to 77.1) |
| Week 24 | 75.9 (62.8 to 86.1) | 62.1 (48.4 to 74.5) |
| Week 36 | 72.5 (56.1 to 85.4) | 60.5 (44.4 to 75.0) |
| Week 52 | 65.6 (46.8 to 81.4) | 62.1 (42.3 to 79.3) |
| Week 64 | 60.0 (36.1 to 80.9) | 73.7 (48.8 to 90.9) |
| Week 76 | 68.4 (43.4 to 87.4) | 62.5 (35.4 to 84.8) |
| Week 88 | 76.9 (46.2 to 95.0) | 71.4 (41.9 to 91.6) |
| Week 104 | 77.8 (40.0 to 97.2) | 66.7 (38.4 to 88.2) |
Clinical Response was defined as having clinical remission CDAI or \>=100-point decrease from baseline in CDAI score where, clinical remission was considered as CDAI \<150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
| Percentage of participants | SS4: Etrasimod 2 mg | SS4: Etrasimod 3 mg |
|---|---|---|
| Week 12 | 84.9 (72.4 to 93.3) | 78.9 (66.1 to 88.6) |
| Week 24 | 86.2 (74.6 to 93.9) | 77.6 (64.7 to 87.5) |
| Week 36 | 82.5 (67.2 to 92.7) | 81.4 (66.6 to 91.6) |
| Week 52 | 78.1 (60.0 to 90.7) | 86.2 (68.3 to 96.1) |
| Week 64 | 80.0 (56.3 to 94.3) | 84.2 (60.4 to 96.6) |
| Week 76 | 78.9 (54.4 to 93.9) | 81.3 (54.4 to 96.0) |
| Week 88 | 84.6 (54.6 to 98.1) | 92.9 (66.1 to 99.8) |
| Week 104 | 77.8 (40.0 to 97.2) | 80.0 (51.9 to 95.7) |
Clinical remission was defined as PRO2 score \<8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
| Percentage of participants | SS4: Etrasimod 2 mg | SS4: Etrasimod 3 mg |
|---|---|---|
| Week 12 | 60.4 (46.0 to 73.5) | 40.4 (27.6 to 54.2) |
| Week 24 | 63.8 (50.1 to 76.0) | 43.1 (30.2 to 56.8) |
| Week 36 | 62.5 (45.8 to 77.3) | 53.5 (37.7 to 68.8) |
| Week 52 | 59.4 (40.6 to 76.3) | 48.3 (29.4 to 67.5) |
| Week 64 | 50.0 (27.2 to 72.8) | 57.9 (33.5 to 79.7) |
| Week 76 | 47.4 (24.4 to 71.1) | 50.0 (24.7 to 75.3) |
| Week 88 | 69.2 (38.6 to 90.9) | 64.3 (35.1 to 87.2) |
| Week 104 | 44.4 (13.7 to 78.8) | 53.3 (26.6 to 78.7) |
Collected over AEs: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: SSA= 82.1 weeks, SS1= 19.9 weeks, SS3= 38.0 weeks, SS4= 166.3 weeks; maximum follow-up: SSA= 86.1 weeks, SS1= 23.9 weeks, SS3= 42 weeks and SS4= 170.3 weeks); All-cause mortality: From randomization through end of the study (maximum of 170.3 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SSA: Placebo in Induction Period | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| SSA: Etrasimod 2 mg in Induction Period | 0/42 (0%) | 2/42 (4.8%) | 19/42 (45.2%) |
| SSA: Etrasimod 3 mg in Induction Period | 0/41 (0%) | 1/41 (2.4%) | 21/41 (51.2%) |
| SSA: Placebo in Induction Period/Etrasimod 3 mg in Extension Period | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) |
| SSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension Period | 0/28 (0%) | 4/28 (14.3%) | 19/28 (67.9%) |
| SSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension Period | 0/2 (0%) | 1/2 (50%) | 2/2 (100%) |
| SSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension Period | 0/34 (0%) | 5/34 (14.7%) | 23/34 (67.6%) |
| SS1: Placebo in Induction Period | 0/100 (0%) | 6/100 (6%) | 45/100 (45%) |
| SS1: Etrasimod 2 mg in Induction Period | 0/98 (0%) | 11/98 (11.2%) | 40/98 (40.8%) |
| SS1: Etrasimod 3 mg in Induction Period | 0/97 (0%) | 9/97 (9.3%) | 34/97 (35.1%) |
| SS1: Placebo in Induction Period/Etrasimod 2 mg in Extended Induction Period | 0/17 (0%) | 0/17 (0%) | 6/17 (35.3%) |
| SS1: Placebo in Induction Period/Etrasimod 3 mg in Extended Induction Period | 0/18 (0%) | 2/18 (11.1%) | 9/18 (50%) |
| SS1: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extended Induction Period | 0/37 (0%) | 3/37 (8.1%) | 11/37 (29.7%) |
| SS1: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extended Induction Period | 0/36 (0%) | 3/36 (8.3%) | 6/36 (16.7%) |
| SS3 Responder Cohort: Placebo/Placebo | 0/47 (0%) | 2/47 (4.3%) | 31/47 (66%) |
| SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | 0/38 (0%) | 4/38 (10.5%) | 24/38 (63.2%) |
| SS3 Responder Cohort: Etrasimod 2 mg/Placebo | 0/33 (0%) | 3/33 (9.1%) | 20/33 (60.6%) |
| SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | 0/28 (0%) | 6/28 (21.4%) | 17/28 (60.7%) |
| SS3 Responder Cohort: Etrasimod 3 mg/Placebo | 0/35 (0%) | 4/35 (11.4%) | 15/35 (42.9%) |
| SS3 Non-responder Cohort: Etrasimod 2 mg | 0/38 (0%) | 5/38 (13.2%) | 17/38 (44.7%) |
| SS3 Non-responder Cohort: Etrasimod 3 mg | 0/23 (0%) | 4/23 (17.4%) | 11/23 (47.8%) |
| SS4: Etrasimod 2 mg | 1/72 (1.4%) | 10/72 (13.9%) | 43/72 (59.7%) |
| SS4: Etrasimod 3 mg | 0/71 (0%) | 8/71 (11.3%) | 36/71 (50.7%) |
| Event | SSA: Placebo in Induction Period | SSA: Etrasimod 2 mg in Induction Period | SSA: Etrasimod 3 mg in Induction Period | SSA: Placebo in Induction Period/Etrasimod 3 mg in Extension Period | SSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension Period | SSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension Period | SSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension Period | SS1: Placebo in Induction Period | SS1: Etrasimod 2 mg in Induction Period | SS1: Etrasimod 3 mg in Induction Period | SS1: Placebo in Induction Period/Etrasimod 2 mg in Extended Induction Period | SS1: Placebo in Induction Period/Etrasimod 3 mg in Extended Induction Period | SS1: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extended Induction Period | SS1: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extended Induction Period | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg | SS4: Etrasimod 2 mg | SS4: Etrasimod 3 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Peri-Rectal AbscessInfections and infestations | 0/1 | 0/42 | 0/41 | 1/1 | 0/28 | 0/2 | 0/34 | 0/100 | 0/98 | 0/97 | 0/17 | 0/18 | 0/37 | 0/36 | 0/47 | 0/38 | 0/33 | 0/28 | 0/35 | 0/38 | 0/23 | 0/72 | 0/71 |
| NephrolithiasisRenal and urinary disorders | 0/1 | 0/42 | 0/41 | 0/1 | 0/28 | 1/2 | 0/34 | 0/100 | 0/98 | 0/97 | 0/17 | 0/18 | 0/37 | 0/36 | 0/47 | 0/38 | 0/33 | 0/28 | 0/35 | 0/38 | 0/23 | 0/72 | 1/71 |
| Crohn's diseaseGastrointestinal disorders | 0/1 | 0/42 | 1/41 | 0/1 | 1/28 | 0/2 | 2/34 | 1/100 | 4/98 | 3/97 | 0/17 | 1/18 | 1/37 | 2/36 | 1/47 | 0/38 | 2/33 | 1/28 | 3/35 | 3/38 | 0/23 | 2/72 | 1/71 |
| MalnutritionMetabolism and nutrition disorders | 0/1 | 0/42 | 0/41 | 0/1 | 1/28 | 0/2 | 0/34 | 0/100 | 1/98 | 0/97 | 0/17 | 1/18 | 0/37 | 0/36 | 0/47 | 0/38 | 0/33 | 0/28 | 0/35 | 0/38 | 0/23 | 0/72 | 0/71 |
| Abdominal painGastrointestinal disorders | 0/1 | 0/42 | 0/41 | 0/1 | 0/28 | 0/2 | 1/34 | 0/100 | 0/98 | 0/97 | 0/17 | 0/18 | 0/37 | 0/36 | 0/47 | 1/38 | 0/33 | 1/28 | 0/35 | 2/38 | 0/23 | 0/72 | 1/71 |
| Abdominal abscessInfections and infestations | 0/1 | 0/42 | 0/41 | 0/1 | 0/28 | 0/2 | 0/34 | 0/100 | 1/98 | 0/97 | 0/17 | 0/18 | 0/37 | 0/36 | 0/47 | 0/38 | 0/33 | 1/28 | 0/35 | 0/38 | 1/23 | 0/72 | 0/71 |
| Acute kidney injuryRenal and urinary disorders | 0/1 | 0/42 | 0/41 | 0/1 | 0/28 | 0/2 | 0/34 | 0/100 | 0/98 | 0/97 | 0/17 | 0/18 | 0/37 | 0/36 | 0/47 | 1/38 | 0/33 | 0/28 | 0/35 | 0/38 | 1/23 | 1/72 | 0/71 |
| Clostridium difficile infectionInfections and infestations | 0/1 | 0/42 | 0/41 | 0/1 | 0/28 | 0/2 | 0/34 | 0/100 | 0/98 | 0/97 | 0/17 | 0/18 | 0/37 | 0/36 | 0/47 | 0/38 | 0/33 | 0/28 | 0/35 | 0/38 | 1/23 | 1/72 | 0/71 |
| PneumoniaInfections and infestations | 0/1 | 0/42 | 0/41 | 0/1 | 0/28 | 0/2 | 0/34 | 0/100 | 0/98 | 0/97 | 0/17 | 0/18 | 0/37 | 0/36 | 0/47 | 0/38 | 0/33 | 0/28 | 0/35 | 0/38 | 1/23 | 0/72 | 0/71 |
| COVID-19Infections and infestations | 0/1 | 0/42 | 0/41 | 0/1 | 1/28 | 0/2 | 1/34 | 0/100 | 0/98 | 0/97 | 0/17 | 0/18 | 0/37 | 0/36 | 0/47 | 0/38 | 0/33 | 0/28 | 0/35 | 0/38 | 0/23 | 0/72 | 0/71 |
| Event | SSA: Placebo in Induction Period | SSA: Etrasimod 2 mg in Induction Period | SSA: Etrasimod 3 mg in Induction Period | SSA: Placebo in Induction Period/Etrasimod 3 mg in Extension Period | SSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension Period | SSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension Period | SSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension Period | SS1: Placebo in Induction Period | SS1: Etrasimod 2 mg in Induction Period | SS1: Etrasimod 3 mg in Induction Period | SS1: Placebo in Induction Period/Etrasimod 2 mg in Extended Induction Period | SS1: Placebo in Induction Period/Etrasimod 3 mg in Extended Induction Period | SS1: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extended Induction Period | SS1: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extended Induction Period | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg | SS4: Etrasimod 2 mg | SS4: Etrasimod 3 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/1 | 4/42 | 8/41 | 0/1 | 3/28 | 1/2 | 4/34 | 3/100 | 9/98 | 9/97 | 0/17 | 2/18 | 1/37 | 2/36 | 7/47 | 7/38 | 3/33 | 3/28 | 3/35 | 3/38 | 2/23 | 6/72 | 2/71 |
| COVID-19Infections and infestations | 0/1 | 2/42 | 4/41 | 0/1 | 2/28 | 1/2 | 7/34 | 6/100 | 1/98 | 4/97 | 0/17 | 1/18 | 2/37 | 0/36 | 1/47 | 2/38 | 2/33 | 1/28 | 3/35 | 0/38 | 3/23 | 0/72 | 0/71 |
| NauseaGastrointestinal disorders | 0/1 | 4/42 | 1/41 | 0/1 | 0/28 | 1/2 | 2/34 | 8/100 | 7/98 | 8/97 | 0/17 | 1/18 | 1/37 | 0/36 | 2/47 | 0/38 | 0/33 | 1/28 | 2/35 | 2/38 | 1/23 | 0/72 | 0/71 |
| Abdominal painGastrointestinal disorders | 0/1 | 0/42 | 0/41 | 0/1 | 1/28 | 1/2 | 3/34 | 9/100 | 13/98 | 1/97 | 0/17 | 0/18 | 3/37 | 1/36 | 4/47 | 3/38 | 2/33 | 2/28 | 5/35 | 6/38 | 2/23 | 6/72 | 3/71 |
| DiarrhoeaGastrointestinal disorders | 0/1 | 0/42 | 0/41 | 0/1 | 0/28 | 1/2 | 1/34 | 0/100 | 0/98 | 0/97 | 0/17 | 1/18 | 1/37 | 0/36 | 4/47 | 3/38 | 1/33 | 0/28 | 2/35 | 2/38 | 2/23 | 0/72 | 0/71 |
| Abdominal tendernessGastrointestinal disorders | 0/1 | 0/42 | 0/41 | 0/1 | 0/28 | 1/2 | 0/34 | 0/100 | 0/98 | 0/97 | 0/17 | 0/18 | 0/37 | 0/36 | 0/47 | 0/38 | 0/33 | 0/28 | 0/35 | 0/38 | 0/23 | 0/72 | 0/71 |
| Clostridium difficile infectionInfections and infestations | 0/1 | 0/42 | 0/41 | 0/1 | 3/28 | 1/2 | 0/34 | 0/100 | 0/98 | 0/97 | 0/17 | 0/18 | 0/37 | 0/36 | 1/47 | 1/38 | 0/33 | 3/28 | 1/35 | 0/38 | 0/23 | 4/72 | 3/71 |
| DysmenorrhoeaReproductive system and breast disorders | 0/1 | 0/42 | 0/41 | 0/1 | 0/28 | 1/2 | 0/34 | 0/100 | 0/98 | 0/97 | 0/17 | 0/18 | 0/37 | 0/36 | 0/47 | 0/38 | 0/33 | 0/28 | 0/35 | 0/38 | 0/23 | 0/72 | 0/71 |
| Crohn's diseaseGastrointestinal disorders | 0/1 | 0/42 | 0/41 | 0/1 | 7/28 | 0/2 | 7/34 | 8/100 | 4/98 | 3/97 | 1/17 | 2/18 | 0/37 | 0/36 | 8/47 | 5/38 | 5/33 | 3/28 | 2/35 | 9/38 | 1/23 | 8/72 | 9/71 |
| HeadacheNervous system disorders | 0/1 | 5/42 | 8/41 | 0/1 | 3/28 | 0/2 | 6/34 | 8/100 | 6/98 | 7/97 | 0/17 | 2/18 | 3/37 | 1/36 | 1/47 | 3/38 | 1/33 | 3/28 | 0/35 | 3/38 | 0/23 | 0/72 | 0/71 |
Eligible participants who completed treatment and met the study specific criteria in SS1 entered SS3 and eligible participants from SS3 and SSA who completed at least 52 and 66 weeks of treatment, respectively entered SS4; hence, participants are not exclusive. To avoid risk of re-identification of participant, baseline measure data is not disclosed for reporting arm SSA: Placebo in Induction Period and reported under category-Not Disclosed.
| Age, Customized(Participants) | SSA: Placebo in Induction Period | SSA: Etrasimod 2 mg in Induction Period | SSA: Etrasimod 3 mg in Induction Period | SS1: Placebo in Induction Period | SS1: Etrasimod 2 mg in Induction Period | SS1: Etrasimod 3 mg in Induction Period | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg | SS4: Etrasimod 2 mg | SS4: Etrasimod 3 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SSA — <=18 years | 0 | 0 | 0 | — | — | — | — | — | — | — | — | — | — | — | — | 0 |
| SSA — Between 18 and 65 years | 0 | 42 | 39 | — | — | — | — | — | — | — | — | — | — | — | — | 81 |
| SSA — >=65 years | 0 | 0 | 2 | — | — | — | — | — | — | — | — | — | — | — | — | 2 |
| SSA — Not Disclosed | 1 | 0 | 0 | — | — | — | — | — | — | — | — | — | — | — | — | 1 |
| SS1 — <=18 years | — | — | — | 0 | 0 | 0 | — | — | — | — | — | — | — | — | — | 0 |
| SS1 — Between 18 and 65 years | — | — | — | 95 | 94 | 94 | — | — | — | — | — | — | — | — | — | 283 |
| SS1 — >=65 years | — | — | — | 5 | 4 | 3 | — | — | — | — | — | — | — | — | — | 12 |
| SS1 — Not Disclosed | — | — | — | 0 | 0 | 0 | — | — | — | — | — | — | — | — | — | 0 |
| SS3 — <=18 years | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | 0 |
| SS3 — Between 18 and 65 years | — | — | — | — | — | — | 45 | 36 | 33 | 28 | 33 | 15 | 12 | — | — | 202 |
| SS3 — >=65 years | — | — | — | — | — | — | 2 | 2 | 0 | 0 | 2 | 0 | 0 | — | — | 6 |
| SS3 — Not Disclosed | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | 0 |
| SS4 — <=18 years | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 0 | 0 |
| SS4 — Between 18 and 65 years | — | — | — | — | — | — | — | — | — | — | — | — | — | 68 | 67 | 135 |
| SS4 — >=65 years | — | — | — | — | — | — | — | — | — | — | — | — | — | 4 | 4 | 8 |
| SS4 — Not Disclosed | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 0 | 0 |
| Sex/Gender, Customized(Participants) | SSA: Placebo in Induction Period | SSA: Etrasimod 2 mg in Induction Period | SSA: Etrasimod 3 mg in Induction Period | SS1: Placebo in Induction Period | SS1: Etrasimod 2 mg in Induction Period | SS1: Etrasimod 3 mg in Induction Period | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg | SS4: Etrasimod 2 mg | SS4: Etrasimod 3 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SSA — Female | 0 | 22 | 19 | — | — | — | — | — | — | — | — | — | — | — | — | 41 |
| SSA — Male | 0 | 20 | 22 | — | — | — | — | — | — | — | — | — | — | — | — | 42 |
| SSA — Not Disclosed | 1 | 0 | 0 | — | — | — | — | — | — | — | — | — | — | — | — | 1 |
| SS1 — Female | — | — | — | 49 | 48 | 46 | — | — | — | — | — | — | — | — | — | 143 |
| SS1 — Male | — | — | — | 51 | 50 | 51 | — | — | — | — | — | — | — | — | — | 152 |
| SS1 — Not Disclosed | — | — | — | 0 | 0 | 0 | — | — | — | — | — | — | — | — | — | 0 |
| SS3 — Female | — | — | — | — | — | — | 22 | 17 | 17 | 11 | 19 | 5 | 5 | — | — | 96 |
| SS3 — Male | — | — | — | — | — | — | 25 | 21 | 16 | 17 | 16 | 10 | 7 | — | — | 112 |
| SS3 — Not Disclosed | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | 0 |
| SS4 — Female | — | — | — | — | — | — | — | — | — | — | — | — | — | 43 | 28 | 71 |
| SS4 — Male | — | — | — | — | — | — | — | — | — | — | — | — | — | 29 | 43 | 72 |
| SS4 — Not Disclosed | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | SSA: Placebo in Induction Period | SSA: Etrasimod 2 mg in Induction Period | SSA: Etrasimod 3 mg in Induction Period | SS1: Placebo in Induction Period | SS1: Etrasimod 2 mg in Induction Period | SS1: Etrasimod 3 mg in Induction Period | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg | SS4: Etrasimod 2 mg | SS4: Etrasimod 3 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SSA — Hispanic or Latino | 0 | 4 | 1 | — | — | — | — | — | — | — | — | — | — | — | — | 5 |
| SSA — Not Hispanic or Latino | 0 | 36 | 38 | — | — | — | — | — | — | — | — | — | — | — | — | 74 |
| SSA — Unknown or Not Reported | 0 | 2 | 2 | — | — | — | — | — | — | — | — | — | — | — | — | 4 |
| SSA — Not Disclosed | 1 | 0 | 0 | — | — | — | — | — | — | — | — | — | — | — | — | 1 |
| SS1 — Hispanic or Latino | — | — | — | 2 | 7 | 10 | — | — | — | — | — | — | — | — | — | 19 |
| SS1 — Not Hispanic or Latino | — | — | — | 93 | 89 | 81 | — | — | — | — | — | — | — | — | — | 263 |
| SS1 — Unknown or Not Reported | — | — | — | 5 | 2 | 6 | — | — | — | — | — | — | — | — | — | 13 |
| SS1 — Not Disclosed | — | — | — | 0 | 0 | 0 | — | — | — | — | — | — | — | — | — | 0 |
| SS3 — Hispanic or Latino | — | — | — | — | — | — | 0 | 5 | 2 | 3 | 5 | 0 | 0 | — | — | 15 |
| SS3 — Not Hispanic or Latino | — | — | — | — | — | — | 45 | 32 | 30 | 24 | 27 | 15 | 12 | — | — | 185 |
| SS3 — Unknown or Not Reported | — | — | — | — | — | — | 2 | 1 | 1 | 1 | 3 | 0 | 0 | — | — | 8 |
| SS3 — Not Disclosed | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | 0 |
| SS4 — Hispanic or Latino | — | — | — | — | — | — | — | — | — | — | — | — | — | 6 | 4 | 10 |
| SS4 — Not Hispanic or Latino | — | — | — | — | — | — | — | — | — | — | — | — | — | 65 | 63 | 128 |
| SS4 — Unknown or Not Reported | — | — | — | — | — | — | — | — | — | — | — | — | — | 1 | 4 | 5 |
| SS4 — Not Disclosed | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | SSA: Placebo in Induction Period | SSA: Etrasimod 2 mg in Induction Period | SSA: Etrasimod 3 mg in Induction Period | SS1: Placebo in Induction Period | SS1: Etrasimod 2 mg in Induction Period | SS1: Etrasimod 3 mg in Induction Period | SS3 Responder Cohort: Placebo/Placebo | SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg | SS3 Responder Cohort: Etrasimod 2 mg/Placebo | SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg | SS3 Responder Cohort: Etrasimod 3 mg/Placebo | SS3 Non-responder Cohort: Etrasimod 2 mg | SS3 Non-responder Cohort: Etrasimod 3 mg | SS4: Etrasimod 2 mg | SS4: Etrasimod 3 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SSA — American Indian or Alaska Native | 0 | 0 | 0 | — | — | — | — | — | — | — | — | — | — | — | — | 0 |
| SSA — Asian | 0 | 1 | 1 | — | — | — | — | — | — | — | — | — | — | — | — | 2 |
| SSA — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | — | — | — | — | — | — | — | — | — | — | — | — | 0 |
| SSA — Black or African American | 0 | 1 | 3 | — | — | — | — | — | — | — | — | — | — | — | — | 4 |
| SSA — White | 0 | 38 | 34 | — | — | — | — | — | — | — | — | — | — | — | — | 72 |
| SSA — More than one race | 0 | 0 | 0 | — | — | — | — | — | — | — | — | — | — | — | — | 0 |
| SSA — Unknown or Not Reported | 0 | 2 | 3 | — | — | — | — | — | — | — | — | — | — | — | — | 5 |
| SSA — Not Disclosed | 1 | 0 | 0 | — | — | — | — | — | — | — | — | — | — | — | — | 1 |
| SS1 — American Indian or Alaska Native | — | — | — | 0 | 1 | 1 | — | — | — | — | — | — | — | — | — | 2 |
| SS1 — Asian | — | — | — | 8 | 4 | 4 | — | — | — | — | — | — | — | — | — | 16 |
| SS1 — Native Hawaiian or Other Pacific Islander | — | — | — | 0 | 0 | 0 | — | — | — | — | — | — | — | — | — | 0 |
| SS1 — Black or African American | — | — | — | 2 | 1 | 2 | — | — | — | — | — | — | — | — | — | 5 |
| SS1 — White | — | — | — | 80 | 87 | 81 | — | — | — | — | — | — | — | — | — | 248 |
| SS1 — More than one race | — | — | — | 0 | 0 | 0 | — | — | — | — | — | — | — | — | — | 0 |
| SS1 — Unknown or Not Reported | — | — | — | 10 | 5 | 9 | — | — | — | — | — | — | — | — | — | 24 |
| SS1 — Not Disclosed | — | — | — | 0 | 0 | 0 | — | — | — | — | — | — | — | — | — | 0 |
| SS3 — American Indian or Alaska Native | — | — | — | — | — | — | 0 | 1 | 0 | 0 | 1 | 0 | 0 | — | — | 2 |
| SS3 — Asian | — | — | — | — | — | — | 5 | 0 | 1 | 1 | 1 | 1 | 2 | — | — | 11 |
| SS3 — Native Hawaiian or Other Pacific Islander | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | 0 |
| SS3 — Black or African American | — | — | — | — | — | — | 0 | 0 | 2 | 0 | 2 | 0 | 1 | — | — | 5 |
| SS3 — White | — | — | — | — | — | — | 39 | 36 | 28 | 25 | 27 | 11 | 8 | — | — | 174 |
| SS3 — More than one race | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | 0 |
| SS3 — Unknown or Not Reported | — | — | — | — | — | — | 3 | 1 | 2 | 2 | 4 | 3 | 1 | — | — | 16 |
| SS3 — Not Disclosed | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | 0 |
| SS4 — American Indian or Alaska Native | — | — | — | — | — | — | — | — | — | — | — | — | — | 1 | 0 | 1 |
| SS4 — Asian | — | — | — | — | — | — | — | — | — | — | — | — | — | 2 | 4 | 6 |
| SS4 — Native Hawaiian or Other Pacific Islander | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 0 | 0 |
| SS4 — Black or African American | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 1 | 1 |
| SS4 — White | — | — | — | — | — | — | — | — | — | — | — | — | — | 65 | 63 | 128 |
| SS4 — More than one race | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 0 | 0 |
| SS4 — Unknown or Not Reported | — | — | — | — | — | — | — | — | — | — | — | — | — | 4 | 3 | 7 |
| SS4 — Not Disclosed | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 0 | 0 |
Showing the first 100 of 510 sites across 41 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jan 2020 to primary completion in Apr 2025, 63 months.
Results were first posted in Jul 2026, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Etrasimod